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ABSTRACT 
 
Activated microglia promote central nervous system (CNS) inflammation through antigen 
presentation and secretion of pro-inflammatory cytokines and chemokines. Although this 
activation is necessary to protect the brain during infection, aberrant release of pro-inflammatory 
and/or cytotoxic factors such as tumor necrosis factor-α, interleukin-1β, nitric oxide and reactive 
oxygen substances may lead to neuronal damage and degeneration.  
Targeting microglia during neuroinflammation to regulate the expression of cytokines without 
affecting other cell types in the CNS is challenging since no specific microglial markers have yet 
been established that distinguish microglia from infiltrating, peripheral myeloid cells. Therefore, 
we propose that a viral-based gene delivery system might be a better strategy to regulate gene 
expression in microglia. Using the recombinant Adeno-associated virus (AAV) vector pseudotype 
2/5, which preferentially infects microglia (, we constructed a plasmid backbone which contains 
GFP under the control of the F4/80 promoter, a macrophage-specific marker. In order to 
demonstrate the specificity of this promoter for macrophages, we transfected human kidney cells 
HEK 293 cells, mouse leukemic macrophages RAW 264.7 cells, human hepatocytes cell line 
(HepG2) and human ovarian carcinoma cell line (1A9) with the AAV-F4/80-eGFP construct or the 
control plasmid AAV-CAG-eGFP. Our results indicate that the rAAV-F4/80-GFP construct is 
selective for macrophages.  
To begin to assess the usefulness of this system to alter microglia function, we have cloned the 
Membrane Associated Ring-CH protein (MARCHI) into the rAAV-F4/80-eGFP vector that has been 
shown earlier to regulate antigen presentation by inducing the intracellular sequestration of MHC 
class II. We were able to confirm this finding by transfecting interferon gamma stimulated 
macrophages cell line RAW 264.7 cells via our constructed AAV-F4/80-MARCHI-eGFP vector and 
demonstrate the ability of our recombinant AAV vector that is driven by specific promoter to 
deliver and express MARCHI to induce MHC class II sequestration. Together this work will lead to 
the development of tools that will allow us to dissect the pathways by which microglia promote 
neuroinflammation. 
 
  Page 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my parents 
my husband Tarik and my three daughters Aya, Lamis and Yousra 
 
 
 
 
 
 
 
 
 
 
 
  Page 4 
 
 
ACKNOWLEDGMENT 
 
First of all, I would like to thank A.Prof Anne LaFlamme for giving me the opportunity to do research in her 
laboratory,  for her excellent support and guidance she gave me throughout my post-graduation studies, 
and for her valuable advice, she was always encouraging me to pursue my own initiatives. 
I would like to thank A.Prof Bronwen Connor for providing me the support I needed in the  AAV production 
experiments. 
To Laura ,Jessica, Jenni, Deegy and Arun, my best friends, thank you for your huge support and advice you 
gave me throughout my thesis and for invaluable help which I couldn’t have done without. Thank you for 
your true amazing friendship. 
Thank you to Prof. John millar, Prof. Bill Jordan, Dr Lifeng Peng, A.Prof David Ackerley, A.Prof Paul Teesdale-
Spittle, for your excellent advice and support. 
Thank you to LAF group and my friends; Lisa,  Sarrabeth, Maddie, Marie, Nikki, Pirooz, for your huge 
support and for helping me understanding ‘’George” the FACS machine. 
Thank you to all people of the SBS school Vichy, Arian, Bhumi, Christina, Sara, Namol, Jonathan, Christine, 
Yee, Ploi, James, Peter Bosh and Alistaire for your amazing help and for saving my time and my experiments 
by lending me reagents. 
To all the SBS staff and faculty of science staff especially to Patricia, Mark and Shauna Desein, thank you so 
much for making things easier for me in the administration. 
To my parents, who have provided unwavering moral support throughout all my life and who have always 
encouraged me to pursue my studies. Thank you for your loving support and for giving me a good 
education. 
To my brothers Ferhat, Djafer, Abdellah and sisters Nadjet, Souhila, Meriem and Nadia; Thank you very 
much for encouraging me and giving me the enthusiasm to continue my studies.  
To my dear husband Tarik, thank you so much for making things easier for me by taking care of the girls 
while I was studying, thank you for encouraging me to pursue my own intrest, without your support this 
thesis would not have been possible. 
Finally to my little princesses Aya, Lamis and Yousra, thank you for being patient and for understanding that 
mumy is busy and needs to be good in her studies. I am sure one of you will be a scientist in the future.  
  Page 5 
 
 
TABLE OF CONTENTS 
 
ABSTRACT .......................................................................................................................................................... 2 
ACKNOWLEDGMENT ......................................................................................................................................... 4 
TABLE OF CONTENTS ......................................................................................................................................... 5 
TABLE OF FIGURES ............................................................................................................................................ 8 
LIST OF ABBREVIATIONS ................................................................................................................................. 10 
Chapter 1    Introduction ................................................................................................................................. 11 
1.1 Biology of AAV ................................................................................................................................. 11 
1.1.1 AAV Classification and serotypes ............................................................................................ 11 
1.1.2 AAV structure and genome map ............................................................................................. 12 
1.1.3 AAV infection and replication process .................................................................................... 14 
1.1.4 AAV life cycle ........................................................................................................................... 16 
1.2 Recombinant AAV vector................................................................................................................. 17 
1.2.1 AAV vector design .................................................................................................................... 17 
1.2.2 Recombinant AAV production strategies ................................................................................ 18 
1.2.3 Recombinant AAV vectors and gene therapy .......................................................................... 21 
1.3 Microglia .......................................................................................................................................... 24 
1.3.1 Microglia in the healthy brain ................................................................................................. 24 
1.3.2 Microglia in neurodegenerative diseases ................................................................................ 27 
1.4 MARCH-I .......................................................................................................................................... 29 
1.5 F4/80 ................................................................................................................................................ 31 
1.6 Thesis objectives .............................................................................................................................. 33 
Chapter 2    General Methods ........................................................................................................................ 34 
2.1 Molecular biology techniques ......................................................................................................... 34 
2.1.1 Escherichia coli DH5alpha chemically competent cells ........................................................... 34 
  Page 6 
 
2.1.2 Chemically competent cells transformation ........................................................................... 34 
2.1.3 Plasmid preparation ................................................................................................................ 35 
2.1.4 AAV shuttle construction ......................................................................................................... 38 
2.2 Mammalian Cell lines culture and assays ........................................................................................ 41 
2.2.1 Mammalian cell lines culture .................................................................................................. 41 
2.2.2 Mammalian Cell lines transfection and use of fluorescence microscope ............................... 42 
2.2.3 IA/IE surface expression assay ................................................................................................. 42 
2.3 Flow cytometry ................................................................................................................................ 43 
2.4 Statistics ........................................................................................................................................... 43 
2.5 AAV2/5-F4/80 virus production ...................................................................................................... 44 
2.5.1 HEK 293 cells triple transfection .............................................................................................. 44 
2.5.2 AAV purification ....................................................................................................................... 45 
2.5.3 AAV stocks Titering .................................................................................................................. 48 
Chapter 3    Reprogramming of recombinant AAV into microglia specific vector ........................................ 50 
3.1 Introduction ..................................................................................................................................... 50 
3.2 Results ............................................................................................................................................. 51 
3.2.1 Construction of AAV-F4/80-eGFP ............................................................................................ 51 
3.2.2 The F4/80 promoter drove eGFP expression in RAW 264.7 cells but not in HEK 293 cells..... 55 
3.2.3 The F4/80 promoter did not drive eGFP expression in HepG2 and 1A9 cell lines .................. 62 
3.3 Discussion ........................................................................................................................................ 64 
3.3.1 AAV-F4/80 shuttle vector construction ................................................................................... 64 
3.3.2 F4/80 promoter specificity investigation ................................................................................ 64 
Chapter 4     Recombinant AAV2/5 production ............................................................................................. 66 
4.1 Introduction ..................................................................................................................................... 66 
4.2 Results ............................................................................................................................................. 70 
4.2.1 AAV2/5-F4/80 packaging via HEK 293 transient transfection ................................................. 70 
4.2.2 Purification and Titering of AAVs Virions ................................................................................ 72 
4.3 Discussion ........................................................................................................................................ 79 
  Page 7 
 
4.3.1 Transient Transfection ............................................................................................................. 79 
4.3.2 AAV Packaging ......................................................................................................................... 80 
4.3.3 AAV Purification ....................................................................................................................... 81 
Chapter 5     AAV-mediated MARCH-I expression and functional testing .................................................... 84 
5.1 Introduction ..................................................................................................................................... 84 
5.2 Results ............................................................................................................................................. 85 
5.2.1 Construction of AAV vector containing the MARCH-I cDNA ................................................... 85 
5.2.2 MHC class II expression on RAW 264.7 cells ........................................................................... 87 
5.2.3 Functional AAV-Mediated MARCH-I expression testing in RAW 264.7 ................................... 91 
5.3 Discussion ...................................................................................................................................... 104 
Chapter 6    General discussion .................................................................................................................... 107 
6.1 AAV-mediated gene delivery ......................................................................................................... 107 
6.2 Microglia role in neurodegeneration investigation ....................................................................... 110 
6.3 Future prospects ............................................................................................................................ 112 
 
 
 
 
 
 
 
 
 
 
 
 
  Page 8 
 
 
TABLE OF FIGURES 
 
Figure 1.1 The wild type AAV genome organization  
Figure 1.2 Wild type AAV virus life cycle 
Figure 1.3 Comparison between wild type AAV and recombinant AAV vector 
Figure 1.4  Inflammatory factors expressed from activated microglia 
Figure 1.5 structure of the longer forms of the EGF-TM7 family members (F4/80, EMR1 and CD97) 
Figure 2.1 Empty AAV plasmid backbone map 
Figure 2.2 Iodixanol density gradient steps 
Figure 2.3 Iodixanol density gradient for the purification of AAV 
Figure 3.1 PCR screening of transformed E.coli colonies 
Figure 3.2 AAV-F4/80-eGFP clone confirmation 
Figure 3.3 AAV-F4/80-eGFP vector plasmid map 
Figure 3.4 eGFP was expressed under both F4/80 and CAG promoters in RAW 264.7 cells 
Figure 3.5 Similar eGFP expression was found with the AAV-CAG-eGFP or AAV-F4/80-eGFP 
plasmids 
Figure 3.6 eGFP expression percentage was equivalent under control of both promoters. 
Figure 3.7 EGFP expression was extremely low under F4/80 promoter control in HEK 293.   
Figure 3.8 Increasing the amount of AAV-F4/80-eGFP plasmid did not boost GFP expression in HEK 
293 
Figure 3.9 EGFP expression was not induced under F4/80 promoter control in HEK 293 
Figure 3.10 F4/80 Vs CAG in HEK and RAW cells 
Figure 3.11 F4/80 promoter did not induce eGFP expression in HepG2 cells 
Figure 3.12 F4/80 promoter did not induce eGFP expression in 1A9 cells 
  Page 9 
 
Figure 4.1  Recombinant Adeno-Associated virus vector production flow chart 
Figure 4.2 HEK 293 cells  transient  transfection 
Figure 4.3  AAV2 DNA Standard Curve 
Figure 4.4  AAV vector stocks were highly contaminated with cellular material 
Figure 4.5  Few RAW 264.7 cells were infected with the packaged AAV2/5-F4/80 virus   
Figure 4.6  Few RAW 264.7 cells were infected with the packaged AAV2/5-F4/80 virus   
Figure 4.6  Few HEK 293 cells were infected by the AAV2 virus control  
Figure 4.7 Zolotukhin et al. (1999) SDS-PAGE result 
Figure 5.1 AAV-F4/80-MARCH-I-eGFP vector construction and confirmation 
Figure 5.2 MHC-II expression was detected at 1/100 and 1/200 dilutions of PE-IA/IE antibody 
Figure 5.3 All concentrations of INF- γ induced significant up-regulation of MHC-II surface 
expression on RAW 264.7 
Figure 5.4 Good expression of eGFP under both promoters F4/80 and CAG in RAW 264.7 prior to 
IFN-γ stimulation 
Figure 5.5 EGFP expression was stronger under F4/80 promoter than under CAG promoter 
Figure 5.6  A sharp decrease of eGFP fluorescence occurred 24 hr after IFN-γ stimulation 
Figure 5.7 EGFP expressions in transfected cells decreased after RAW 264.7 IFN-γ stimulation 
compared to non-IFN-γ stimulated cells 
Figure 5.8 MHC-II expression was impaired on the surface of AAV-transfected RAW 264.7 cells 
after IFN-γ treatment 
Figure 5.9   EGFP⁺/MHC-II⁻ population was identified in MARCH-I-containing cells but not in CAG-
containing cells 
 
 
 
 
  Page 10 
 
 
LIST OF ABBREVIATIONS 
 
AAV: Adeno-Associated Virus 
MARCH-I: membrane-associated RING (CH) 
MHC-II: Major histocompatibility complex class II 
IFN-γ: Interferon gamma 
IL-10, IL-4: Interleukine 
CAG: CMV/chicken β-actin hybrid 
DMEM: Dulbecco’s modified eagle medium 
IMDM: Iscove’s modified eagle medium 
FACS: Fluorescence-activated cell sorting 
HEK 293: Human embryonic kideny 
RFU: Relative Fluorescence Unit 
BDNF: Brain-Derived Neurotrophic Factor 
NSE: Neuron-Specific Enolase 
CNS: Central Nervous System 
GFP: Green Fluorescent Protein 
YFP: Yellow Fluorescent Protein 
PCR: Polymerase Chain Reaction 
FCS: Foetal Calf Serum 
SDS-PAGE: Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
VP: Viral Protein 
IRES: Internal ribosome entry 
PE: PhycoErythrin 
  Page 11 
 
CHAPTER 1 
INTRODUCTION 
 
1.1 Biology of AAV 
1.1.1 AAV Classification and serotypes 
The AAV virus belongs to the Parvoviridae family and is categorized in the Dependovirus genus, 
since the virus depends on a helper virus such as adenovirus or herpes simplex virus for efficient 
replication (Daya and Berns, 2008; Gonclaves, 2005). Indeed, AAV was originally discovered in 
1965 as a contaminant in rhesus-monkey-kidney cell cultures infected with simian adenovirus type 
15 (SV15) (Atchison, 1965).  
An AAV serotype is defined as an inability of an AAV isolate to cross-react with neutralizing 
antibodies that are reactive to the viral capsid proteins of other isolates (Wu et al., 2006; Choi et 
al., 2005). As of 2008, 12 AAV human serotypes (AAV1-AAV12) had been discovered for which 
humans are the primary host and new serotypes are continuing to be discovered. AAV2 was the 
first serotype identified and the best studied (Cucchiarini et al., 2003; Asokan et al., 2012). 
Although approximately 80% of the human population is seropositive for AAV2, no pathology has 
been associated with this virus (Asokan et al., 2012). Most of the serotypes were isolated from 
adenovirus preparations in the laboratory and have similar structure, genome size and 
organization but different tissue tropism (Wu et al., 2006). For instance, AAV5 was reported to 
have a high tropism for liver tissue and all regions of the CNS (Mingozzi et al., 2002; Davidson et 
al., 2000), while AAV4 was shown to highly transduce ependymal and astrocytes in the CNS 
(Mingozzi et al., 2002; Davidson et al., 2000). AAV1 and AAV7 were shown to have a tropism for 
skeletal muscle (Chao et al., 2000; Gao et al., 2002).  
New serotypes are defined as newly isolated viruses which do not cross-react efficiently with 
neutralizing antibodies, which are specific for other characterized serotypes. Based on this 
definition, Wu et al. suggested that AAV 1-5, 7-9 and 12 are the only types that can be defined as 
true serotypes (Wu et al., 2006). The remaining types 6, 10 and 11 do not seem to fit into the new 
serotype definition. As an alternative they are called AAV variants because of their similarities with 
other serotypes, such as variant 6 with serotype 1, or because they are not well characterized (Wu 
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et al., 2006; Gao et al., 2004; Schmidt et al., 2008) (Table 1.1). However, it was shown previously in 
Xiao et al. that previous treatment of murine liver with AAV2 generated a partial neutralization of 
AAV1 vector.  This partial neutralization of AAV1 did not occur in murine skeletal muscle (Xiao et 
al., 1999), suggesting that cross-reactivity between some AAV serotypes may depend on tissue 
type or species.   
AAV AAV-1 AAV-2 AAV-3 AAV-4 AAV-5 AAV-6 AAV-7 AAV-8 AAV-9 
AAV-1 100         
AAV-2 83 100        
AAV-3 87 88 100       
AAV-4 63 60 63 100      
AAV-5 58 57 58 53 100     
AAV-6 99 83 87 63 58 100    
AAV-7 85 82 85 63 58 85 100   
AAV-8 84 83 86 63 58 84 88 100  
AAV-9 82 82 84 62 57 82 82 85 100 
 
Table 1.1 AAV serotypes capsid homology. (Adapted from Daya and Berns, 2008) 
 
1.1.2 AAV structure and genome map 
AAV is one of the smallest viruses (25 nm) with a non-enveloped icosahedral capsid, packaging a 
linear single-stranded DNA genome, and varies in length between 4642 bp and 4767 bp according 
to the AAV serotypes (Srivastava et al., 1983; Grimm and Kay, 2003). The genome organization of 
serotype 2 was first characterized in 1982 by Srivastava et al. and contains in each termini two 
inverted terminal repeats (ITRs) of 145 nucleotides (Srivastava et al., 1983). The first 125 
nucleotides of the repeat are in the form of a palindromic sequence, folding on itself to maximize 
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base pairing and forming a T-shape hairpin structure (Figure 1.1 A) (Srivastava et al., 1983).  The 
remaining 20 nucleotides are called the D sequence and are unpaired and present only once at 
each end of the genome. ITRs also contain two elements that are crucial for AAV replication; Rep 
binding elements (RBE and RBE’) and the terminal resolution site (trs) (Ryan et al., 1996). The ITRs 
flank two open reading frames (orf) containing the AAV genes rep (replication) and cap (capsid) 
genes encoding non-structural and structural proteins respectively (Figure 1.1 B).  
The rep genes encode four regulatory proteins indicated by their apparent molecular sizes; Rep78, 
Rep68, Rep52 and Rep40, expressed from transcripts using two promoters (p5) and (p19), which 
are located at map positions 5 and 19 respectively. Rep78 and Rep52 are expressed from un-
spliced transcripts while Rep68 and Rep40 are produced from spliced transcripts (Figure 1.1 B) 
(Ryan et al., 1996). The cap gene, expressed under p40 promoter, encodes for three proteins 
composing the AAV capsid: VP1, VP2 and VP3, and these proteins are produced from two 
transcripts. The biggest capsid protein VP1 is 87 kDa and is produced from un-spliced transcript 
while VP2 (72 kDa) and VP3 (62 kDa) are spliced from a single transcript (A. Srivastava et al., 1983).   
The three capsid proteins of AAV2 differ from each other by their N terminus and they assemble 
into an icosahedral protein shell of 60 subunits (93). The three capsid proteins are present at a 
molecular ratio of 1:1:10 (VP1: VP2: VP3) (Daya and Berns, 2008). 
Similar genome organization and capsid morphologies were also found in the other serotypes with 
small differences in genome length (Grimm and Kay, 2003). 
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Figure 1.1 The wild type AAV genome organization. A) ITRs secondary structure containing RBE’, 
RBE, trs and the sequence D, which are involved in AAV replication. B) Map of AAV genome 
showing ITRs at the two ends of the genome flanking rep and cap genes and their promoters’ p5, 
p19 and p40. An alternative ACG codon used for VP3 production is indicated by a star (Daya and 
Berns, 2008).  
 
1.1.3 AAV infection and replication process 
AAV infection starts by AAV attachment to the host cell membrane initiated by the interaction of 
the capsid with cell surface glycosaminoglycan. This attachment is followed by a secondary 
interaction of the viral capsid with a co-receptor inducing AAV internalization and trafficking to the 
nucleus (Wu et al., 2006; Weitzman and Linden, 2011). For AAV2 for instance, the membrane-
associated heparan sulfate proteoglycan was shown to be a receptor for this serotype 
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(Summerford and Samulski, 1998), and this binding was reported to be enhanced by interaction 
with fibroblast growth factor receptor 1 (FGFR1) (Qing et al., 1999), αVβ5 integrin and hepatocyte 
growth factor co-receptors (Summerford et al., 1999; Kashiwakura et al., 2005).  The rapid 
internalization of AAV2 was induced by clathrin-mediated endocytosis (Bartlett et al., 2000). On 
the other hand, AAV5 binding and uptake was shown to be enhanced via sialic acid and platelet-
derived growth factor receptor (PDGF-R) respectively (Di Pasquale et al., 2003). 
The signalling pathway involved in AAV trafficking and entry into the host nucleus remains unclear; 
Bartlett et al. for instance have demonstrated by the use of the lysosomotropic drug ammonium 
chloride and the proton pump inhibitor bafilomycin A1 that, once the virus is internalized into an 
early endosome, its release into the cytosol requires the endosomal lumen acidification to induce 
conformational changes to key capsid subunits that are involved in priming virus endosomal 
escape (Bartlett et al., 2000). Furthermore, it has been suggested that the AAV virus traverses to 
the nucleus, accumulates in the nuclear envelop and slowly penetrates through the nuclear pore 
complex (NPC) into the nucleus (Bartlett et al., 2000). Nevertheless, the AAV nucleus entry 
through NPC hypothesis has been ruled out in Hansen et al. study, as they have shown that 
blocking active NPC-mediated transport did not inhibit the viral entry into the nucleus (Hansen et 
al., 2001).  
Although it is not clear whether AAV uncoating happens before or after nuclear entry, once the 
uncoating process occurs, the single stranded viral genome is converted into a double stranded 
form required for gene expression (Weitzman and Linden, 2011). Rep78/68 proteins were shown 
to interact with RBE and trs sequences to activate the replication process of the viral DNA, and 
regulate gene expression of AAV (Pareira et al., 1997). The small Rep proteins, Rep52 and Rep 40 
are involved in the generation and accumulation of single-stranded AAV genome generated from 
double-stranded templates intermediates and, the helicase activity of these small Rep proteins 
was shown to improve genome encapsidation (Merten et al., 2005; King et al., 2001). VP proteins 
form empty capsids in a rapid reaction in the nucleus and slowly package the single stranded DNA 
(Myers and Carter, 1980).  
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1.1.4 AAV life cycle 
AAV life cycle contains two cycles; a replication productive cycle, known as lytic stage and a latent 
cycle named lysogenic stage (Figure 1.2). The lytic stage takes place in the presence of a helper 
virus that aids in AAV gene expression and alters the cellular environment to induce an AAV 
productive life cycle. The typical helper virus is adenovirus (Daya and Berns, 2008); however 
others such as herpes simplex virus (HSV), vaccinia virus and cytomegalovirus (CMV) were also 
shown to exert helper function for AAV (Hansen et al., 2001;  Schlehofer et al, 1986).  
The helper genes that adenovirus provides for AAV gene expression include E1a, E1b, E2a, E4 and 
the virus associated RNA (VA RNA). It was reported in Shi et al. that the E1a protein stimulates 
YY1-binding site that is involved in transcriptional repression for the p5 promoter of AAV (Shi et 
al., 1991). Furthermore, E2a gene that encodes a single-strand DNA binding protein DBP was 
shown to be necessary for the progressive replication of AAV genome in vitro (Ward et al., 1998). 
The E1b and E4 gene products function as ubiquitin ligases and were shown in Schwartz et al. to 
enhance AAV transduction and replication by inducing degradation of the cellular Mre11 repair 
complex (MRN). This complex was suggested to be critical in DNA damage sensing and repair and 
interferes with AAV replication (Schwartz et al.,2007). In addition, the VA RNA, a small RNA that is 
highly produced during adenovirus infection, was suggested to have a role in stimulating AAV 
proteins expression by preventing eIF2α translation factor phosphorylation, as it was reported 
previously that eIF2α phosphorylation by the serine-threonine kinase protein kinase (PKR), blocks 
translation and expression of viral proteins (Nayak and Pintel, 2007; Mathews and Shenk, 1991).  
The lysogenic stage occurs in the absence of helper virus, in which expression of Rep68/78 is 
limited. In this stage AAV gene expression is repressed leading to AAV genome integration into a 
specific region of the host genome located on chromosome 19 (q13.4) and known as AAVS1 (Daya 
and Berns, 2008; Kotin et al., 1990). This genome integration results in a latent replication that is 
tightly coordinated with that of the host. Nevertheless, once the AAV-infected cell is super-
infected with a helper virus, integrated AAV genome is rescued from the host genome and viral 
genes expression is activated leading to a productive replication (Weitzman and Linden, 2011). 
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Figure 1.2 Wild type AAV virus life cycle. (Daya and Berns, 2008)  
 
1.2 Recombinant AAV vector 
1.2.1 AAV vector design 
Since the first use of recombinant AAV vectors to transduce foreign DNA into human and murine 
culture cells in 1984 (Hermonat and Muzyczka, 1984), the vector underwent several modifications 
to improve its efficacy. Current AAV vectors do not encode Rep and Cap genes and they lack the 
cis-active IEE, a sequence that is required for site specific integration during lysogenic stage. 
Because of these deficiencies, AAV vectors persist primarily in the cytoplasm as double-stranded 
circular or linear episomes (Nakai et al., 2000; Grose et al., 2012). The ITRs are the only part of the 
virus that is kept in cis in the genome as they are required for replication and packaging (Figure 
1.3) (Daya and Berns, 2008). Rep and Cap ORFs are replaced with a gene expression cassette of 
interest, whereas for vector production, Rep and Cap genes are supplied in trans with helper virus 
auxiliary genes which can be from the same serotype or from different serotypes (Cap genes are 
from another serotype). When Rep and Cap genes are from different serotypes, the AAV produced 
is called pseudotype or hybrid serotype (Choi et al., 2005).  
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Figure 1.3. Comparison between wild type AAV and recombinant AAV vector. (Masat et al., 2013) 
 
1.2.2 Recombinant AAV production strategies 
1.2.2.1 Packaging methods 
To ensure high purity, safety and potency of the AAV products, different approaches have been 
used to package AAV vectors. The classical approach used in laboratories for AAV packaging for 
pre-clinical studies is transient transfection of adherent HEK 293 (Fraser Wright, 2009). 
The very first method was based on a two plasmid transfection of packaging cells with AAV vector 
backbone and Rep/Cap plasmid (Fraser Wright, 2009). Like wild type AAV, cells were infected with 
wild type adenovirus few hours later at low multiplicity of infection in order to replicate efficiently 
(Samulski et al., 1989). The drawback of this method was the use of wild type adenovirus which is 
produced as well, resulting in contamination of the purified AAV vector preparations and 
rendering the AAV preparations unsuitable for in vivo studies (Matsushita et al., 1998).  
In order to overcome this challenge, an alternative approach was developed by Matsushita et al. in 
1998, called ‘’a triple transfection method’’, in which AAV vectors were packaged without helper 
virus infection (Matsushita et al., 1998). In this approach, the adenovirus subset genes that are 
necessary for AAV replication including E4, E2A, VA RNA were cloned into a separate plasmid and 
co-transfected into HEK 293 cells along with pRep/Cap and AAV vector plasmids. The E1 gene is 
another necessary adenovirus helper gene and it is supplied by HEK 293 cells. AAV titer obtained 
from the helper-free method was equal to that achieved by adenovirus infection with same 
potency (Matsushita et al., 1998). Consequently, this method generated AAV preparations free of 
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detectable adenoviral particles (Matsushita et al., 1998). The advantage of this approach is the 
simultaneous production of AAV serotypes and hybrids, which is convenient for preclinical studies 
in which AAV vectors characteristic need to be tested. On the other hand, transient transfection of 
adherent HEK 293 method is difficult to scale up and a number of studies are focusing on 
improving this technology to make it more efficient for clinical purposes (Liu et al., 2003; Asokan 
et al. 2011).  
The most relevant methods used for DNA plasmid transfer into the packaging cell for AAV 
production include calcium phosphate precipitation, polyethylenimine (PEI) precipitation and 
cationic lipids (Fraser Wright, 2009). Of these methods, calcium phosphate-mediated transfection 
has been extensively used to produce AAV vectors for preclinical studies (Chen et al., 1998; Grose 
et al., 2013; Klein et al., 1998). 
Stable producer cell line is another method used to package the viral vector (Merten et al., 2005). 
This approach is based on production of AAV in HeLa cells, the chosen producer cell line in this 
method due to their ability in rescuing integrated copies of AAV very efficiently compared with 
HEK293 (Blouin et al., 2004). In this method, AAV Rep and Cap genes and ITR-AAV sequence are 
integrated in the producer cell line genome requiring only adenovirus infection to produce the 
virions, thus eliminating the need of transfection (Nakamura et al., 2004). However, while in 
preclinical studies AAV serotype and genome need to be selected and optimized, AAV production 
system needs more versatility than this method allows. Moreover, the presence of the human 
papilloma virus (HPV 18) sequence in these cells makes them potentially dangerous to use for AAV 
preparations destined to human clinical trials (Schwarz et al., 1985).  
The Baculovirus-insect cells method is another strategy used for AAV vectors production. This 
approach was established in 2004 by Urabe et al. and is based on infection of invertebrate cells 
Spodoptera frugiperda (Sf9) cells that are cultured in suspension, with three recombinant 
baculoviruses: a Rep-baculovirus containing Rep78 and Rep52 genes, a VP-baculovirus expressing 
AAV capsid proteins and an ITR-AAV-baculovirus (Urabe et al., 2004). Although this strategy was 
shown to generate equivalent amounts of AAV particles as in HEK cell transient transfection 
(Urabe et al., 2004; Viraq et al., 2009), the instability of the baculovirus is very challenging as it 
depends on the passage number of the insect cell (Virag et al., 2009). Another disadvantage of 
using this technique is the contamination of the AAV stocks with the recombinant baculoviruses.  
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1.2.2.2 Purification methods 
A variety of purification strategies are used in laboratories. Some labs favour a combination of 
density gradient ultracentrifugation and chromatography while others chose to perform one-step 
purification using a density gradient or chromatography (Zolotukhin et al., 1999; Schmidt et al., 
2008). The conventional density gradient method for AAV purification is caesium chloride (CsCl), 
which is still used in many studies (Zolotukhin et al., 1999; Iwata et al., 2013; Xiao et al., 1998). 
However, the challenge in using this reagent is the large amount of time spent in performing 
multiple rounds of CsCl gradients to decontaminate AAV stocks from aggregates leading to poor 
AAV recovery and affecting AAV infectivity when the stocks are not properly purified (Zolotukhin 
et al., 1999; Auricchio et al., 2001). Furthermore, precautions must be taken when handling the 
reagent as it is a chemical hazard. In particular, before transduction of cells, the AAV vectors stock 
must be cesium chloride-free due to the reagent toxicity to cells.  
Since discontinuous iodixanol density gradient was adapted by Zolotukhin et al, it became the 
preferred method in many laboratories to purify AAV vectors, due to its iso-osmotic and inertness 
properties at all densities (Zolotukhin et al., 1999). Additionally, its non-toxicity to cells makes AAV 
purification steps quicker when AAV infectivity assays need to be performed directly on AAV-
iodixanol gradient fractions without further purification (Iwata et al., 2013; Li et al., 2006). In 
addition, in terms of AAV vector infectivity, iodixanol gradients were shown to generate the most 
infective AAV vectors over CsCl (Zolotukhin et al., 1999). The common drawback of both gradients 
is the limited loading capacity for AAV samples which can impede large scale production of AAV 
vectors.  
Chromatographic methods used for AAV purification were first established when AAV2 interaction 
with the HSPG receptor was observed. The subsequent identification of the host receptors used by 
other AAV serotypes facilitated the development of this approach. The most extensively used 
chromatographic methods include affinity chromatography and ion-exchange chromatography 
(Smith et al., 2008). Affinity chromatography is used to purify AAV serotypes and variants that 
have the ability to bind to heparan sulfate including AAV2, AAV6 and AAV3a/3b clone (Kaludov et 
al., 2002) but since AAV serotypes display different capsids proteins, the use of this method is 
restricted to few serotypes only. Ion exchange chromatography on the other hand,  is more 
versatile since this method is based on the ionic charge properties of the AAV vectors in solution, 
permitting the purification of the serotypes with known glycan receptors such as AAV4, AAV5, 
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AAV2, AAV1, AAV8 ( Davidoff et al., 2004; Brument et al., 2002). Although chromatographic 
approach has been shown to achieve higher yields and purity of AAV stocks compared to density 
gradient ultracentrifugation methods, this method requires careful optimization at each step. 
Furthermore, empty capsids are not excluded from the purified AAV stocks comparing with 
iodixanol gradient density approach. To circumvent this issue, many studies have combined 
density gradient ultracentrifugation and chromatography to improve the yield and purity of the 
AAV products. In addition, others have implemented new  strategies  such as the two-step 
purification method involving a strong cation exchange chromatography resin (SP sepharose HP) 
coupled with a strong anion exchange chromatography resin (source 15Q) ( Brument et al., 2002), 
or an anion chromatography using a strong anion exchange resin followed by gel filtration 
chromatography (Smith et al., 2003). 
 
1.2.3 Recombinant AAV vectors and gene therapy 
Gene therapy consists of delivering therapeutic DNA into a target cell to replace a mutated or 
translocated gene or to regulate a gene expression in order to repair the cell dysfunction. This new 
approach is very promising vis-a-vis traditional therapies and has been evolving since the first gene 
therapy trials (phase 1) for adenosine deaminase (ADA) deficiency and malignant melanoma in 
1990 (Walther and Stein, 2000).  Two methods are used to facilitate the transfer of gene of 
interest into the target cell; the viral vectors method and the non-viral vectors method. The non-
viral approach uses chemical based vectors including cationic lipids, cationic polymers and 
inorganic nanoparticles or physical forces such as electroporation, sonoporation and 
hydrodynamic gene transfer (Al-Dosari and Gao, 2009).  
The viral vectors-based approach, the most extensively used method in gene delivery, employs a 
genetically modified virus or ‘’recombinant virus’’. This method more efficiently transfers the 
desired gene into the target cell compared with non-viral methods in which transgene expression 
is at lower level (Al-Dosari and Gao, 2009). A number of DNA and RNA viruses have been widely 
utilized to generate these viral vectors such as adenovirus, herpes simplex virus (HSV), retrovirus 
and AAV. The difference between these vectors includes the size of the gene insert, the duration 
of expression, target cell infectivity and integration of the vector genome into the host genome 
(Table 1.2).  
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Table 1.2 Characteristics of the most employed viral vectors in gene therapy. (Adapted from 
Kathy Ponder, 2001)   
 
The desired features of a viral vector in clinical applications include 1) stable and efficient gene 
expression to accomplish therapeutic effects, 2) a capacity to harbour a large therapeutic gene, 
and 3) high infectivity. Retroviruses and HSV vectors for instance, possess these features as they 
both maintain therapeutic genes permanently in the host cell, have a large genome (>8kb and > 
25kb respectively) and very infective (Kathy Ponder, 2001). Nevertheless, although these vectors 
have shown to achieve promising outcomes in human gene therapy clinical trials (Kathy Ponder, 
2001; Walther and Stein, 2000), these vectors do not satisfy safety requirements. The risk of 
insertional mutagenesis is higher when using retroviruses (Yi et al., 2011); for example, it was 
reported in a human clinical trial where an ex-vivo gene transfer by retrovirus was performed on 
nine infants with X-linked severe combined immunodeficiency (X-SCID), that leukemia developed 
in four of them despite the success of the therapy (Yi et al., 2011). Furthermore, vectors based 
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upon HSV-1 were reported to be challenging due to their toxicity to cells and development of wild-
type HSV-1 which can cause encephalitis (Walther and Stein, 2000; Manservigi et al., 2010). In 
addition, adenovirus, HSV and retrovirus vectors are immunogenic and thus, they are not suitable 
for sustained gene therapy (Wu and Ertl, 2009). 
AAV vector in the other hand, has become very popular in preclinical and clinical trials due to it 
very attractive features including, its ability to stably express transgenes in the target cell in 
episomes, ability to infect dividing and non-dividing cells and the lack of pathology linked to AAV 
compared with other viral vectors (Kay et al., 2001). Furthermore, no adverse effects have been 
reported so far in clinical trials, in particular in brain disorders such as Parkinson’s disease and 
retinal diseases (Mueller and Flotte, 2008). For instance, in Jacobson et al. study on human retinal 
disorder RPE65-deficient Leber congenital amaurosis (LCA), AAV2 delivery of the RPE65 gene 
(retinal pigment epithelium-specific protein 65 kDa) to the retina of blind RPE65-deficient dogs 
restored their vision with no systemic toxicity and only a mild inflammation that was localised at 
the site of injection and which resolved over 3 months (Jacobson et al., 2006). In addition, to 
assess the safety of the retinal administration of AAV2-RPE56, a phase I clinical trial has been 
conducted on three patients having LCA, and no side effects have been reported (Jacobson et al., 
2006).  In another study, a unilateral stereotaxic infusion of 12 patients with advanced Parkinson’s 
disease (PD) was carried to transfer the glutamic acid decarboxylase (GAD) gene via AAV vector 
directly into the subthalamic nucleus (STN), in attempt to alter STN activity that is increased in PD 
patients. The treatment was restricted to only one hemisphere of the brain to reduce the risks of 
any side effect that might occur. A significant improvement was observed in PD patients with no 
detectable toxicity or any side effects observed for more than 3 years after surgery (Kay et al., 
2001; Kaplitt et al., 2007).  
Although AAV vector is poorly immunogenic, a low immune response to the AAV capsid proteins 
has been observed in some clinical trials (McPhee et al., 2006; Mano et al., 2006), but several 
strategies have been considered to evade the host immune response such as transient 
immunosuppression (Mingozzi et al., 2007), in which AAV vector delivery is coupled with an 
immunosuppressive agent.  Another approach involves reengineering of AAV capsid and 
generation of serotype mutants (e.g AAV2.15, AAV2.4) containing mutations at key antigenic sites 
(Maheshri et al., 2006). 
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1.3 Microglia 
Microglia are resident macrophage-like cells of the central nervous system (CNS). They perform 
similar functions as other macrophages in the body while protecting and supporting CNS functions 
(Ulvestad et al., 1994). These cells belong to the glial system and are located throughout the brain 
parenchyma (E. Ulvestad et al., 1994), representing around 10% of the non-neuronal cells in adult 
mouse brain (Pintado et al., 2011) and up to 13% in human CNS (Ulvestad et al., 1994). The origin 
of microglia has been controversial since their first description by Franz Nissl in 1880 (Pintado et 
al., 2011); however, evidence has accumulated for cells of hematopoietic origin entering the CNS 
during foetal life (Frederic Vilhardt, 2004; Kettenmann et al., 2011). Microglia density varies 
between brain regions, but the most populated areas include the hippocampus, substantia nigra, 
olfactory telencephalon and basal ganglia (Pintado et al., 2011; Lawson et al., 1990), and they are 
closely connected to both neurons and astrocytes (Trembley and Majewska, 2011).  
 
1.3.1 Microglia in the healthy brain 
In the healthy mature brain, microglia exhibit morphological and functional plasticity and can be 
found in a highly ramified or ameboid macrophage-like morphology (Kettenmann et al., 2011). The 
ramified microglia differ from classical macrophages as they possess a dendritic-like phenotype 
with small rod-shape somata and numerous branching processes (Napoli and Neumann, 2009). 
This phenotype has long been referred to as ‘’resting microglia’’ due to their immobile morphology 
and low activity. Additionally, they express surface receptors at low levels including CD45, CD14 
and CD11b/CD18 (Francesca Aloisi, 2001; Georg W Kreutzberg, 1996; Glenn et al., 1992). However 
Nimmerjahn et al. provided evidence that in fact, these cells are not in a ‘’dormant state’’ but 
instead they are highly dynamic in the resting state in vivo as they constantly changing their 
morphology by extending and retracting highly motile processes in a time scale of minutes 
(Nimmerjahn et al., 2005). Indeed, Ramified microglia were shown to display protrusions of 
variable shapes appearing transiently at the main processes and at their terminal endings, with 
spontaneous swallowing of tissue components that were transported towards the soma, 
suggesting a role in collecting tissue debris and metabolic products (Nimmerjahn et al., 2005). 
Thus ramified microglia were suggested to have a role in a constant surveillance of their own 
microenvironment in order to maintain CNS homeostasis (Nimmerjahn et al., 2005; Perry and 
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Teeling, 2013). Furthermore, Vinet et al. have reported in their recent in vitro study, that ramified 
microglia possess neuroprotective properties as well. By implementing an in vitro system 
comparable to the in vivo conditions, they were able to demonstrate the essential role of ramified 
microglia in protecting dentate gyrus and CA3 neurons N methyl-D-aspartic acid (NMDA)-induced 
excitotoxicity (Vinet et al., 2012).   
During infection, injury or ischemia in the CNS, signals from stressed or damaged cells, immune 
cells or pathogens activate microglia, which are rapidly transformed into an ameboid macrophage-
like shape. These activated microglia actively move to the site of injury or infection following a 
chemotactic gradient and proliferate (Kettenmann et al., 2011; Georg W Kreutzberg, 1996; Rogove 
et al., 2002). The early sign of activated microglia in response to CNS inflammation is the up-
regulation of MHC class II and adhesion molecules (Francesca Aloisi, 2001; Georg W Kreutzberg, 
1996). MHC molecules presenting antigenic peptides on the surface of microglia play a crucial role 
in stimulating protective T-cell responses against infection, tumoral cells and certain inflammatory 
conditions. Adhesion molecules CD58, CD54 and CD11b as well as co-stimulatory molecules CD40, 
CD80 and CD86 are also involved in this interaction for an optimal antigen presentation function 
(Francesca Aloisi, 2001).  
 These resident macrophages secrete pro-inflammatory cytokines, reactive oxygen species (ROS), 
nitrogen intermediates to destroy invading agents, but these factors can also act as neurotoxins 
and damaged tissue. However, microglia also produce neuroprotective factors to repair damaged 
neurons and restore CNS homeostasis (Frederik Vilhardt, 2004). The proinflammatory cytokines 
induced by activated microglia include pleiotropic cytokines, which have a role in humoral and 
cellular immune responses induction, such as IL-6, IL-12, IL-18 and IL-15 (Francesca Aloisi, 2001), 
and TNF-α and IL-1β. TNF-α and IL-1β are the two major proinflammatory cytokines produced by 
activated microglia and macrophages. TNF-α has been shown to have a critical role in promoting 
microglia phagocytosis and inducing inflammatory cytokines production that may have a role in 
protecting the CNS against LPS and bacteria (Francesca Aloisi, 2001). In addition, TNF-α was 
reported to have a neurotoxic effect as it inhibits the re-uptake of the primary excitatory 
neurotransmitter glutamate by astrocytes inducing an accumulation of extracellular glutamate 
generating higher and toxic concentrations of this neurotransmitter (Rogove and Tsirka, 1997).  
 IL-1β is another critical proinflammatory cytokine that is suggested to be a major activator of 
astrocytes (Paul Moynagh, 2005). It was shown to be the key cytokine to induce the expression of 
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type II inducible nitric oxide synthase (iNOS) in astrocytes, which have a role in vasodilatation (Liu 
et al., 1996). IL-1β was also shown to stimulate the transcription factor NF-κB that induces 
adhesion molecules and chemokines expression such as IL-8, VCAM-1 and ICAM-1 in astrocytes 
(Paul Moynagh, 2005).  
Rogove and Tsirka have demonstrated in their study that inhibition of activated microglia by 
macrophage migration inhibitory factor (MIF) in an excitotoxin-mediated brain injury model 
system resulted in resistance in neuronal death and attenuation of microglia activity (Rogove and 
Tsirka, 1997). Furthermore, in the same study, the amount of microglia-derived tissue 
plasminogen activator (tPA), a serine protease that is produced from both microglia and neurons, 
was found reduced (Rogove and Tsirka, 1997). The same investigators showed previously that tPA 
is rapidly produced from microglia upon an excitotoxic insult to induce neuronal cell destruction 
(Rogove and Tsirka. 1996). In addition, it was reported that the major source of tPA at the site of 
injury is microglia (Rogove and Tsirka. 1997; Rogove et al., 2002). These findings suggest that 
microglia have a toxic effect on affected neurons while non-affected neurons are not destroyed by 
activated microglia (Rogove and Tsirka, 1997; Gehrmann et al., 1995).  
Other neurotoxic products generated from activated microglia include reactive oxygen species 
which are superoxide (O2⁻) and reactive nitrogen species such as nitric oxide (NO). Moss and Bates 
demonstrated that following LPS and IFN-γ stimulation of murine microglial cell lines, an inducible 
form of nitric oxide synthase NOS is induced  and NO is released into the medium. These products 
were shown to have deleterious effects on brain energy metabolism including inhibition in 
mitochondrial oxidative phosphorylation and a decrease in mitochondrial ATP production as well 
as inhibition of mitochondrial respiratory chain enzyme activities (Moss and Bates, 2001; Brookes 
et al., 1999). 
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Figure 1.4.  Inflammatory factors expressed from activated microglia. (Francesca Aloisi, 2001) 
 
Down regulation of immune responses at site of inflammation in the CNS is necessary to allow 
healing and reduce secretion of pro-inflammatory cytokines, chemokines and infiltration of T 
lymphocytes. The neuronal survival can be compromised when this pro-inflammatory response 
lasts for a long period of time. The down-regulation process involves the production of anti-
inflammatory cytokines including IL-10, TGF-β and IL-4 and IL-1ra (IL-1 receptor antagonist) 
(Tremblay et al., 2011). Cell death by apoptosis is mediated by receptors of TNF-R super-family 
and is also crucial in terminating immune responses in the inflamed CNS (Pender and Rist, 2001).  
 
1.3.2 Microglia in neurodegenerative diseases 
Although the exact mechanism by which innate inflammation contributes to neurodegenerative 
diseases is still unclear, it is now well accepted that microglia are involved in neuroinflammatory 
and neurodegenerative disorders including multiple sclerosis (MS), Alzheimer’s disease (AD) and 
Parkinson’s disease (PD). In response to the insult generated from these disorders, microglia 
become reactive and induce an innate immune response in an attempt to restore CNS 
homeostasis (Napoli and Neumann, 2009). Nevertheless, the repeated stimulation of these local 
macrophages induces a chronic inflammation in which infiltration of other immune cells through 
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the blood brain barrier (BBB) into the parenchyma is increased along with MHC-II expression, 
inflammatory cytokines, oxidative and nitrosative stress, which in fact harms the CNS (Vinet et al., 
2012; Luo and Chen, 2012).  
In MS for instance, the most common chronic inflammatory demyelinating disease of the CNS, 
microglia was reported to have a key role (Ulvestad et al., 1994; Becher et al., 2001). MS is 
characterised by demyelination of axons resulting in neurodegeneration (Wolfgang Bruck, 2005). 
During MS, demyelination is observed in the white matter as focal lesions as well as in the cortical 
and subcortical grey matter (Wolfgang Bruck, 2005). These lesions contain various infiltrating 
immune cells including T-cells, peripheral macrophages and B cells and local immune cells such as 
microglia (Hansen Lassmann, 1999). Remyelination is also observed in MS lesions following the 
resolution of acute inflammatory episodes in up to 40% of MS lesions (Wolfgang Bruck, 2005).   
Numerous studies have shown the direct contribution of activated microglia in myelin sheath 
destruction and induction of chronic inflammation. It was reported by Lucchienetti et al. that the 
loss of oligodendrocytes (OG) in MS lesions correlated with an increased number of microglia and 
infiltrating macrophages secreting excitotoxic factors such as TNF-α, IL-1β and reactive antigen 
intermediates (Lucchinetti et al., 1999). The persistent release of these neurotoxins can be 
detrimental to myelin and oligodendrocytes (Lucchinetti et al., 1999; Diemel et al., 1998). 
Furthermore, it was reported that in early MS lesions, microglia are the major phagocytes that 
contain myelin debris and peripheral macrophages are recruited as the lesions develop (Diemel et 
al., 1998).  
In addition, these cells may participate in the remyelination of demyelinated MS lesions (Wolfgang 
Bruck, 2005; Graca and Blakemore, 1986). Indeed, it was previously demonstrated that in induced 
demyelination of areas in the white matter of the lumbar rat spinal cord by ethidium bromide, 
remyelination was delayed in the glia free regions where few macrophages were observed (Graca 
and Blakemore, 1986). In addition, in vitro studies showed that microglia produced growth factors 
including fibroblast growth factor-2 (FGF-2), transforming growth factor-β1 (TGFβ1), nerve growth 
factor (NGF), and neurotrophins. Neutrophins are produced from both microglia and macrophages 
which may be released during remyelination mechanism to induce myelinogenesis and 
oligodendrocytes proliferation and survival (Diemel et al., 1998).  
Microglia involvement in Parkinson’s disease has also been studied extensively. This 
neurodegenerative disorder is characterized by a progressive degeneration of dopaminergic cells 
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in the substancia nigra, a region that has a crucial role in the body movements (Hamani and 
Lozano, 2003). This region is highly populated with microglia and the intensity of the LPS-induced 
inflammation (TNF-α, IL-1, ROS) was reported to be positively correlated with microglial cell 
density in vivo (Pintado et al., 2011). Another feature of the substancia nigra which makes it highly 
susceptible to inflammation is, the higher blood brain barrier permeability (BBB) suggesting that 
plasma cytokines released from systemic inflammation or infectious agents, could penetrate the 
BBB and activate microglia in this region (Pintado et al., 2011). In fact, it was reported that an 
infection with a certain type of viruses or a previous traumatic brain injury may induce later in life 
a post-encephalitic Parkinsonism (Liu and Hong, 2003). In Alzheimer’s disease in the other hand, in 
which β-Amyloid (Aβ) proteins are aggregated both within neurons and the extracellular space, 
microglia were found surrounding Aβ plaques in both humans and animal models of AD (Prokop et 
al., 2013).  in vivo studies have reported an increase in IL-1, IL-12, IL-23 and complement proteins 
in the amyloid plaques, and in in vitro numerous inflammatory cytokines were expressed following 
stimulation of microglia with the Aβ peptides derived from the amyloid precursor protein (APP), 
suggesting the reactivity of microglia in AD (Prokop et al., 2013; Ransohoff and  Perry, 2009).  All 
these findings are consistent with the involvement of microglia in neurodegenerative disorders; 
however, more studies are needed to identify the key pathways to chronic inflammation in order 
to establish the right treatments for these disorders.  
 
1.4 MARCH-I 
Ubiquitination is an essential control mechanism in cell growth and proliferation by causing the 
down-regulation of receptors and transporters by rapid endocytosis and degradation of 
ubiquitinated substrate proteins (Ohmura-Hoshino et al., 2006). Three enzymes are required for 
this role including ubiquitin-activating enzyme E1 which activates ubiquitin and transfers it to the 
ubiquitin-carrier enzyme E2 and ubiquitin-ligase E3 catalyses activated ubiquitin (Hershko and 
Ciechanover, 1998). Nine human membrane-associated RING-CH (MARCH) proteins have been 
identified belonging to the E3 ubiquitin ligases family (Bartee et al., 2004). These proteins were 
found structurally and functionally related to the viral E3-ubiquitin ligases such as K3, K5 and mK3 
(Ohmura-Hoshino et al., 2006; Bartee et al., 2004), and these viral ubiquitin ligases were shown to 
induce ubiquitination of MHC-I molecules and other co-stimulatory molecules such as ICAM-1, 
CD86 (B7.2) and CD1d (Lehner et al., 2005).    
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MARCH-I is one of the ubiquitin ligase E3 family members and is homologous to MARCH-VIII. Both 
proteins were shown to induce ubiquitination and downregulation of MHC-I, MHC-II, CD86 (B7.2), 
CD95 (Fas) and transferrin receptor (Tfr) surface expression (E. Bartee et al., 2004). While MARCH-
VIII is broadly expressed (Bartee et al., 2004), MARCH-I is highly expressed in secondary lymphoid 
tissues particularly in resting APCs including B cells, dendritic cells (DCs) and monocytes (Cho and 
Roch, 2013).  MARCH-I was shown to be the only ubiquitin ligase to down-regulate MHC-II surface 
expression in B cells (Matsuki et al., 2007), and in DCs, MARCH-I is the major regulator of MHC-II 
ubiquitination (De Gassart et al., 2008). In mouse macrophages, human monocytes and B cells, IL-
10 was shown to up-regulate MARCH-I expression which induced MHC-II ubiquitination 
(Thibodeau et al., 2008; Cho and Roch, 2013). MARCH-I expression is down-regulated in mature 
APCs (Lai et al., 2010), and was reported to be significantly reduced in  APCS stimulated with toll-
like receptor (TLR) signals (Walseng et al., 2010; Cho and Roch, 2013). The exact mechanism by 
which MHC-II is ubiquitinated by MARCH-II is still not fully understood. Data obtained from 
Walseng et al. showed that MARCH-I induced MHC-II degradation following ubiquitination in 
immature DCs and this degradation was blocked at 40% only in MARCH-I knockout DCs within 6h 
compared with wild type control, in which the MHC-II degradation was at 70 % (Walsenga et al., 
2010). These findings suggest that another pathway may be involved in the MHC-II degradation in 
immature DCs. 
When expressed, MARCH-I is rapidly degraded with an estimated half-life of <30 min in primary 
APCs and their cell lines. This decrease in stability may be regulated by auto-ubiquitination and 
other factors that have not been identified yet (Jabbour et al., 2009), and the mechanism by which 
MARCH-I is degraded is still not fully elucidated. However, it was demonstrated by Jabbour et al. 
that a portion of MARCH-I was degraded by the proteasome since this ubiquitin ligase was 
partially stabilized by treatment of DCs with a proteasome inhibitor (MG132) (Jabbour et al., 
2009). Furthermore, the same study showed that inhibition of lysosomal peptidases led to a stable 
expression of MARCH-I in immature bone marrow DCs, and therefore both proteasome and 
lysosome pathways are involved in the degradation of MARCH-I proteins (Jabbour et al., 2009). In 
addition, the N-terminus domain was shown to be directly involved in the stability of MARCH-I in 
the cytoplasm (Jabbour et al., 2009). 
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1.5 F4/80 
F4/80 is a mouse antigen marker that its expression is restricted to macrophages (Gordon et al., 
2011). Three decades ago, the F4/80 monoclonal antibody was described by Austyn and Gordon 
that was found to react specifically against a 160 kDa antigen on mouse macrophages after the 
immunization of rats with thioglycollate-elicited mouse peritoneal macrophages (Austyn and 
Gordon, 1981). No reactivity was observed for other hematopoietic cells of myeloid lineage 
(Austyn and Gordon, 1981). the antibody was found to react against macrophages from different 
sites such as blood monocytes, spleen and peritoneal cavity (Austyn and Gordon, 1981).  
F4/80 is a 160 kDa glycoprotein, belongs to the EGF-TM7 family and represents the longer form of 
this family along with EMR1 (EGF module-containing, mucin-like hormone receptor 1) the human 
ortholog of F4/80 and CD97. F4/80 protein comprises seven extracellular EGF-like domains at the 
N-terminus followed by a Ser/Thr-rich spacer region linked to the C-terminal of the GPCR-related 
MT7 domain (G-protein-coupled seven-transmembrane-spanning hormone receptor) (McKnight 
and Gordon, 1998; Lin et al., 2010) (Figure 1.5).  
F4/80 is expressed during the foetal life and throughout the adult life and its presence is strictly 
correlated with the distribution of macrophages. It was demonstrated previously that 
macrophages cell lineage appears in the mouse embryo around day 10 of gestation in the yolk sac, 
liver followed by spleen and surrounding mesenchymal tissues (De Felici et al., 1986; Takahashi et 
al., 1989; Morris et al., 1991).  Indeed, in Hopkinson et al., study on the limb embryo, F4/80 
antigens were detected in aorta-gonad-mesonephros (AGM) region and yolk sac at day 8 and 9; 
the expression of the antigen has increased with the development of the embryo and before birth 
in foetal liver, splenic red pulp and bone marrow macrophages (Hopkinson et al., 1994). In the 
adult, F4/80 is highly expressed in the phagocytic cells including Kuppfer cells in the liver, red pulp 
in the spleen, thymic cortex, bone marrow, and adrenal glands as well as in the microglia in the 
CNS and Langerhans cells in the skin (Gordon et al., 2011). However, in monocytes, this expression 
is very low. Therefore, since the identification of this macrophages marker, F4/80 became widely 
used as a marker in macrophages studies (Levin et al., 2012; Imtiyaz et al., 2010; Bilyk et al., 1988).   
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Figure 1.5. structure of the longer forms of the EGF-TM7 family members (F4/80, EMR1 and 
CD97). This image illustrates the structure of the Three longer forms of the EGF-TM7 family which 
are the mouse F4/80, the human EMR1 and CD97. The rat glucagon receptor that is the shorter 
form and lacking the EGF domain is shown for comparison. EGF domain is represented by triangles 
and the N-linked glycosylation sites are shown in black circles. The ss are disulphide bonds 
between the first and the extracellular loops. F4/80 contains O-linked sugars shown as short black 
bars and the GAG represents the glycosaminoglycan modification (McKnight and Gordon, 1998).  
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1.6 Thesis objectives 
This thesis aims to construct and optimize an AAV tool that can be used to investigate the role of 
microglia in neuroinflammatory disorders such as multiple sclerosis. The first aim of this thesis is 
to construct a macrophage/microglia-specific adeno-associated virus (AAV) vector by inserting the 
F4/80 promoter sequence into the ITR-plasmid backbone. Our hypothesis is that this AAV vector 
driven by the F4/80 promoter will be expressed exclusively in macrophages and CNS-resident 
microglia. By achieving this, the expression of the gene of interest in microglia could be controlled 
and the risk of off-target expression reduced. 
After testing the specificity of the viral vector, the second aim is to optimize the production of the 
AAV vector based on pseudotype 2/5 using the most commonly employed production strategy 
calcium-phosphate mediated triple transfection for AAV2/5 packaging followed by a discontinuous 
iodixanol density gradient ultracentrifugation. By producing these AAV particles, we could test 
their tropism for microglia and potency in infecting the cells by monitoring its pathway in vitro or 
in vivo via enhanced green fluorescent protein (eGFP).  
The final aim is to investigate the role of MARCH-I molecule, an E3 ubiquitin ligase shown to have 
a crucial role in regulating MHC-II expression. MARCH-I will be inserted into the AAV-F4/80-eGFP 
vector and its function tested on IFN-γ-stimulated macrophages-like cells (RAW 264.7). Our 
hypothesis is that IFN-γ-primed MHC-II surface expression will be inhibited following the forced 
expression of MARCH-I in RAW 264.7 cells. The ability to down-regulate MHC-II expression on 
activated microglia using this viral tool could provide a better understanding of the role of these 
cells in neuroinflammation.  
 
 
 
 
 
 
 
  Page 34 
 
CHAPTER 2 
GENERAL METHODS 
 
2.1 Molecular biology techniques 
2.1.1 Escherichia coli DH5alpha chemically competent cells 
E.coli DH5α λpir (Invitrogen, Carlsbad, CA, USA) was cultured for 16 h on agar without antibiotics at 
37°C. Five to ten mL of TYM broth culture were inoculated with a single colony and incubated for 
16 h at 37°C on a shaker (Bioline, London, UK) at 200 rpm. Once the optic density (OD600) reached 
3.0 – 4.0, 100 μL of overnight culture was added to 40 mL TYM broth media.  Cells were grown to 
an OD600 of 0.35-0.40, were immediately chilled on ice for 20 min and spun at 3000 g for 10 min at 
4°C. Three mL of cold TFB I was added to the pellet and resuspended by pipetting. Then the 
volume was bought to 40 mL using same solution, and it was incubated on ice for 2 - 3 h. Cells 
were centrifuged at 3000 g for 10 min at 4°C, resuspended in 4 mL ice cold TFB II (Appendix), and 
stored in 100 µL aliquots at -80°C until use. 
 
2.1.2 Chemically competent cells transformation  
To transform competent DH5α cells, 5 µL of plasmid DNA (Table 2.1) was added to 100 µL of 
competent cells in a 1.7 mL eppendorf tube and mixed gently. A Puc19 plasmid control (Invitrogen) 
was used to monitor transformation efficiency. Tubes were incubated on ice for 30 min followed 
by a heat shock for 45 seconds to 2 min in a 42°C water bath or heat block, and placed again on ice 
for further 2 - 15 min. 600 μL of pre-warmed LB medium (Appendix 4) was added to each tube and 
incubated at 37°C on the shaker at 225 rpm for 1 h. 100 µL of each transformation mixture was 
plated onto antibiotic-containing agar plates and incubated overnight at 37°C (Table 2.1). 
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Plasmid 
name 
           Plasmid construct Supplier Antibiotic 
resistance  
Empty AAV 
backbone          
          pFBAAVmcsIRESeGFPBgHpA Gene transfer 
vector core 
Gentamicin/Am
picillin 
AAV-CAG           pFBAAVCAGmcsIRESeGFPBgHpA Gene transfer 
vector core 
Gentamicin/Am
picillin 
pHelper           pSR449B     Robert Kotin Lab                               Ampicillin 
pRep/Cap                               pAAVRep2/Cap5 Colleen Stein-
Davidson Lab             
Ampicillin 
AAV-yfp           pAMCAG-dYFP-WPRE-BgHpA                    Bronwen Connor 
Lab 
Ampicillin 
MARCHI 
cDNA donor            
          pCMV6-AC-GFP Origen  Ampicillin/Neo
mycin 
F4/80 
promoter 
donor 
          pEZX-PG02 GeneCopoeia™  Kanamycin 
AAV-F4/80 pFBAAVF4/80mcsIRESeGFPBgHpA                         Gentamicin/Am
picillin 
AAV-F4/80-
MARCHI             
          pFBAAVF4/80MARCHImcsIRES 
          eGFPBgHpA        
 Gentamicin/Am
picillin 
 
Table 2.1 Source of Plasmids  
 
2.1.3 Plasmid preparation 
2.1.3.1 Plasmid Miniprep 
Small-scale plasmid purifications were undertaken using a High-speed plasmid mini kit (Geneaid, 
New Taipei, Taiwan). A pellet of 3-4 mL of cultured bacterial cells containing the plasmid of 
interest was obtained by centrifugation at 14-16,000 x g for 1 min. Cells were resuspended in 200 
μL RNase suspension buffer and lysed by adding 200 μL lysis buffer. In order to separate plasmid 
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DNA and cellular debris, 300 μL of chilled binding buffer was added to the tube and centrifuged at 
14-16,000 x g for 3 min. Plasmid DNA-containing supernatant was transferred to a column and 
centrifuged at 14-16,000 x g for 30 sec. The column containing bound plasmids was washed  with 
600 μL of ethanol containing wash buffer and centrifuged twice at 14-16,000 x g for 30 sec and 
then for 3 min to dry the column matrix. To elute plasmid DNA, 50 μL of TE buffer was added to 
the matrix column and the latter was centrifuged at 14-16,000 x g after letting it standing for 2 
min. 
 
2.1.3.2 Plasmid Maxiprep 
Large-scale DNA plasmids purification was performed using PureLink Maxiprep kit (Invitrogen). 250 
mL of DNA plasmid-containing bacterial cell culture was centrifuged at 4000 x g for 10 min. The 
pellet was resuspended in 10 mL of resuspension buffer containing RNase and lysed with 10 mL 
lysis buffer. 10 mL of precipitation buffer was added to the mixture and precipitated lysate was 
transferred into the HiPure filter maxi column and was run through the filter by gravity flow. After 
the lysates stopped dripping, the column was washed with 50 mL of wash buffer and the solution 
was allowed to drain by gravity flow. DNA plasmid was eluted by adding 15 mL of elution buffer to 
the maxi column and precipitated by adding 10.5 mL isopropanol and centrifuged at >12,000 x g 
for 30 min at 4°C. To resuspend the DNA plasmid pellet, 5 mL of 70% ethanol was added to the 
tube and centrifuged at > 12,000 x g for 5 min at 4°C. After leaving the pellet to air-dry for 10 min, 
DNA plasmid pellet was resuspended with 500 μL TE buffer and stored at -20°C.  
 
2.1.3.3 Restriction enzyme digestion reaction  
Restriction digests were performed to prepare plasmids to confirm their identities for use in 
further experiments (Table 2.2) or for cloning (Table 2.3). In a 25 μL reaction, 15 μL of  plasmid 
DNA was added to 5.5 μL of nuclease-free sterile ddH₂O, 2.5 μL of 10x NEB buffer 4 (New England 
Biolabs, MA, USA) and 20 U of each restriction enzyme. The reaction was incubated at 37°C for 3 h 
to overnight.  
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Plasmids                                              RE Expected fragment 
sizes 
AAV-CAG EcoRI/NotI 6960/1404 
pHelper NcoI 4277/4238/1722/1398 
pRep/Cap SalI 5089/1541 
Empty AAV backbone NcoI/NotI 5798/723 
MARCHI donor plasmid NcoI 3876/1215/1166/735/423 
F4/80 donor plasmid EcoRI 4788/875 
 
Table 2.2 Restriction enzymes used for plasmids identification 
 
 
 
 
 
  
Table 2.3 Restriction enzymes used for cloning  
 
2.1.3.4 DNA electrophoresis 
Following restriction enzyme digest, 5 μL of digested DNA fragments from desired plasmid were 
loaded onto 0.9 % low melting point agarose gel in TAE buffer (Appendix 4). DNA fragment size 
was estimated using a 1 kb plus DNA ladder (Invitrogen) suitable for sizing linear double-stranded 
DNA fragments from 100 bp to 12 kb. Electrophoresis was run at 90 V for 120 min, stained for 20 
AAV plasmids cDNA 
insert 
 RE 
AAV backbone F4/80  SalI/NheI 
AAV-F4/80 MARCHI  SpeI/ClaI 
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min with ethidium bromide (Sigma Aldrich, MO, USA), at 0.5 μg/mL and washed with sterile 
ddH₂O. To visualize the bands, AlphaImager® Mini UV System (ProteinSimple, Santa Clara, CA, USA) 
was used. 
 
2.1.4 AAV shuttle construction 
2.1.4.1 PCR primers design  
To isolate the cDNA of interest from its source plasmid, primers shown in Table 2.2 were 
customized, and in order to allow insertion of the PCR-amplified cDNA fragment, unique restriction 
enzymes sites were incorporated that complemented the restriction sites at the multiple cloning 
site of the AAV backbone plasmid. After adding the desired restriction site to the 5’ end of both 
forward and reverse primers, a string of four Cs preceding the restriction site was added in order 
to form a G:C clamp at the end of the amplified PCR product allowing an efficient enzyme cut. NEB 
cutter V2.0 software was used to map restriction sites that are present in the desired plasmid, and 
ClustalW and Oligo Analizer 3.1 (IDT Sci Tools, Coralville, IA,USA) were used to check and analyse 
primers sequences respectively. Primers were manufactured by Integrated DNA Technologies 
(IDT). 
 
cDNA Forward Reverse 
MARCHI 5’CCCCACTAGTATGCCCCTCCACCAGATTTC3’ 
                 SalI   
5’CCCCATCGATGACTGGTATAACCTCAGGTG3’ 
                  NheI 
F4/80 5’CCCCGTCGACATTACAGGTGCCTAACACCA3’ 
                 SpeI                                                                                          
5’CCCCGCTAGCTATGCTGTAGTTCTGTCATT3’ 
             ClaI 
 
Table 2.4 PCR primers sequences 
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2.1.4.2 Standard PCR 
The gene of interest sequence was isolated from its plasmid source via PCR. In a 50 μL reaction, 25 
μL of MyTaq™ Mix (Bioline) was mixed with 20 μM final concentration of each desired cDNA 
forward (IDT) and reverse primers (IDT) and 200 ng of the plasmid source. The PCR reaction was 
set up on ice and the amplification reaction was run on Techne Tc-5000 PCR thermal cycler (GMI, 
Ramsay, MN, USA) under the following conditions: 1 cycle of initial denaturation at 94°C for 3 min, 
35 cycles of: denaturation at 94°C (30 sec), annealing at 57°C (30 sec) and extension at 68°C (30 sec 
per kb). The final extension was at 68°C for 10 min. 
 
2.1.4.3 DNA fragment purification from agarose gel 
To extract PCR or restriction digestion cDNA products from agarose gel for ligation, gel/PCR DNA 
fragments extraction kit (Geneaid) was used following the manufacturer instructions. After 
running the products in an agarose gel electrophoresis (see section 2.1.3.4 for protocol), the 
agarose gel portion containing the relevant DNA fragment was excised and transferred to a 1.5 mL 
microcentrifuge tube. 500 μL of DF buffer containing chaotropic salt was added to the tube and 
the sample was incubated at 55-60°C for 10-15 min to dissolve agarose gel. The dissolved sample 
(800 μL) was transferred to a column after letting it to cool to room temperature, and centrifuged 
at 14-16,000 x g for 30 sec. After binding DNA fragments in chaotropic salt by the glass fibre matrix 
of the spin column, the latter was washed twice with 400 μL W1 buffer and 600 μL ethanol-
containing wash buffer and spun for 30 sec and 3 min respectively at 14-16,000 x g. The purified 
DNA fragments were eluted by adding 50 μL of TE buffer to the column and spinning it for 2 min at 
14-16,000 x g. Purified DNA stocks were stored at -20°C. 
 
2.1.4.4 DNA fragment ligation to the AAV vector backbone    
The empty AAV vector backbone (Figure 2.1) used to construct the AAV-F4/80-eGFP and AA-F4/80-
MARCHI-eGFP vectors was an Invitrogen pFastBac™ plasmid (Gene transfer core, Iowa, USA) 
containing enhanced green fluorescent protein eGFP. The expression of eGFP was further 
enhanced by a Internal Ribosome Entry site element (IRES), and this element is useful in gene 
delivery to coordinate and efficiently express two genes that are under control of same promoter 
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in a single vector. Both eGFP and IRES were flanked by the AAV two inverted terminal repeats (ITR) 
from serotype 2. 
F4/80 promoter ortholog EMR1 “Homo sapiens EGF-like module containing, mucin-like,  hormone 
receptor-like 1”, was PCR amplified from pEZX-PG02 plasmid (GeneCopoeia, Rockville, USA) and 
the mouse membrane-associated ring finger (C3HC4) 1 (MARCH1) cDNA was derived from pCMV6-
AC-GFP vector (Origen, Rockville, USA), using the primers described in Table 2.4 (see Appendix 1 
for the plasmid maps). 
 Inserts were cloned into the empty AAV backbone at their corresponding restriction sites (Table 
2.3) using T4 DNA Ligase (Invitrogen) following the manufacturer’s instructions. Ligation was setup 
with 4 μL of ligase reaction buffer, 0.1 U T4 DNA ligase (5 U/μL), 50 ng AAV vector and 150 ng 
insert (1:3 ratio of vector: insert). The reaction was made up to 20 μL with sterile ddH2O. 
 
 
Figure 2.1 Empty AAV plasmid backbone map 
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2.1.4.5 Colony PCR 
Following transformation of E.coli with ligation products, a colony PCR was performed to screen 
E.coli colonies for the presence of the cDNA sequence of interest in the AAV plasmid. The reaction 
was set up by transferring single colonies to each PCR tube and adding 25 μL of MyTaq™ Mix 
(Bioline) and 20 μM final concentration of each forward and reverse primer that amplified the 
relevant cDNA sequence. PCR reaction was performed as described in section 2.1.4.2. To confirm 
clone identity, agarose gel electrophoresis was performed as described in section 2.1.3.4.   
 
2.1.4.6 ITRs integrity analysis 
As recombination at both the transposable elements (Tn7L and Tn7R) and the ITRs is possible in 
the pFBAAV plasmid throughout cloning process and amplification to midi or maxi preps,   Integrity 
of ITRs in constructed AAV vectors were checked by performing a single digest each of MscI and 
XmaI (New England Biolabs) following the protocol described in section 2.1.3.3. 
 
2.2 Mammalian Cell lines culture and assays 
2.2.1 Mammalian cell lines culture 
Human embryonic kidney 293 cells (HEK), packaging-type, were used to package AAV-F4/80 vector 
because they have the adenovirus gene, early region 1 (E1) containing two transcription units E1a 
and E1b, which is required for AAV packaging. This human cell line was first described in Graham et 
al. and was created by the transformation and culturing of normal human embryonic kidney cells 
with fragment of mechanically sheared DNA of adenovirus serotype 5 (Graham et al., 1977). This 
resulted in the incorporation of approximately 4.5 kilobases from the viral genome into the human 
chromosome 19 of HEK  cells (Louis et al., 1997). Human ovarian carcinoma cell lines 1A9 and 
human hepatocellular carcinoma HePG02 were a kind gift from Professor John Miller (VUW) and 
Dr Lifeng Peng (VUW) respectively.  
The murine macrophage-like cell line RAW 264.7 has been shown to express the same key  surface 
markers (CD11 and F4/80) and to have similar responses to three microbial ligands LPS, Pam₃CSK₄ 
and Poly I:C as bone marrow macrophages (Hartley et al., 2008). RAW cells were established from 
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an Abelson murine leukemia virus (MuLV)-induced tumor developing in a BAB/14 mouse, a 
congenic strain of BALB/c IgH (Hartley et al., 2008). 
All mammalian cell lines were maintained in Dulbecco’s Modified Eagle Medium (DMEM)  
supplemented with 10% foetal calf serum (FCS), 100 units/mL Penicillin/streptomycin, 2mM L-
Glutamine, 2% HEPES and 1% non-essential amino-acids (all reagents from Invitrogen). Cultures 
were incubated at 37°C/5% CO2, and cells were passaged twice weekly to maintain them at their 
exponential growth phase. All cell processing was performed in biosafety cabinets (LABCONCO, 
Kansas, MO, USA). 
 
2.2.2 Mammalian Cell lines transfection and use of fluorescence microscope  
A day before transfection, cells were cultured in a 24 well plate at 0.5 x 10⁶ cells/well in 500 μL 
complete DMEM (see section 2.2.1 for recipe). All cell lines were used at low passage number (< 
20). Once cells were 70-80% confluent, media was changed and replaced with complete DMEM 
with or without antibiotics. Cells were transfected via DNA plasmid using Lipofectamine® LTX and 
PLUS Reagent (Invitrogen). Transfection was performed as per manufacturer instructions. Briefly, 
plasmid DNA was added to 250 μL of Opti-MEM reduced serum medium (Invitrogen).  “PLUS” 
reagent was added to the DNA mix at 1:1 ratio (“PLUS” reagent: DNA) and tubes were incubated 
15 min at room temperature before adding 4 μL of Lipofectamine® LTX reagent. The mixture was 
incubated 30 min at room temperature and 50 μL DNA-Lipofectamine was added to each culture 
well. Non-transfected cells were used as a negative control. Plates were incubated at 37°C/5% CO2 
for 16-24 h then analysed under an Olympus fluorescent microscope (Olympus 1x 51, 
magnification 10x, 4x).  
 
2.2.3 IA/IE surface expression assay 
RAW cells were cultured in 24-well plates at 4 x 10⁵ cells/ well in complete DMEM at 2% FCS with 
antibiotics. To induce IA/IE surface expression, RAW cells were treated with interferon gamma 
(IFN-γ) at 20 U/mL or left untreated as a control. Cells were incubated at 37°C/5% CO2 and 
harvested at 1-3 days later for FACS analysis. At each time point, cells were washed and collected 
with warm dPBS (Gibco™), and cell pellets were obtained by centrifugation at 300 g for 5 min. 
  Page 43 
 
RAW cells were collected in 300 μL ice-cold FACS buffer containing   dPBS supplemented with 2% 
FCS and 0.1% sodium azide (1M). 1 x 10⁶ cells from each sample were transferred to each well in a 
U-bottom 96-well plate, and cell pellets were obtained by centrifugation at 400 g for 5 min. Cells 
were incubated on ice for 10 min with 50 μL of rat anti-CD16/32 at 1:300 (BD Pharmingen, USA) in 
order to block non-specific IgG Fc receptors prior to staining with the antibody. Cells were washed 
with 200 μL FACS buffer and the plate was spun for 5 min at 400 g. Cells were stained with PE-
conjugated rat anti-mouse MHC-II (IA/IE) antibodies (1:200; eBioscience, San Diego, CA, USA) and 
incubated on ice in the dark for 30 min. Each sample was washed with 200 μL of FACS buffer, re-
suspended and filtered through a 70 μm mesh in 300 μL FACS buffer and analysed immediately 
using a BD FACSCanto II (BD Biosciences, USA) flow cytometer. PE-conjugated rat IgG2b, κ isotype 
control antibody (1:200; eBioscience, San Diego, CA, USA) was used as a negative control. 
 
2.3 Flow cytometry 
Samples were acquired on a FACScanto II flow cytometer (BD Bioscience) with FACSDiva 6.1.2 
software. The gated live cell population of interest was determined using the forward scatter (FSC-
A) and side scatter (SSC-A) data of non-stained cells. 5000-10,000 live events were recorded per 
assay. All analyses were carried out using FlowJo software (Tree Star Inc. Ashland, OR, USA).  
 
2.4 Statistics 
To analyse results and generate graphs, GraphPad, Prism v. 4.0 (GraphPad Software, San Diego 
California USA, www.graphpad.com) was used. Tests for significance were performed using one-
way ANOVA with Sidak’s multiple comparison test, comparing multiple treatments with vehicle 
control. P-values under 0.05 were considered significant. 
 
 
 
 
 
  Page 44 
 
2.5 AAV2/5-F4/80 virus production 
2.5.1 HEK 293 cells triple transfection 
All procedures involving AAV virus were performed exclusively in biosafety cabinets. Prior to 
transfection, HEK 293 cells were maintained in complete DMEM (Section 2.2.1). Three 150 cm² 
flasks of HEK 293 cells were plated at 5 x 10⁶ cells/flask for each vector type.  Once cells reached 
80% confluency, the complete DMEM was removed and replaced by Iscove’s modified Dulbecco’s 
media IMDM (high glucose) (Gibco®, USA) 3 h prior to transfection. HEK  cells were transfected 
with three plasmids for each AAV virus type to be packaged (Table 2.5). Helper plasmid contained 
necessary adenovirus genes required for an efficient AAV replication which are E2A, VA, and E4. E1 
adenovirus gene that is also necessary for AAV replication is supplied in HEK 293 cells genome 
(Section 2.2.1). Replication and capsid genes were supplied in trans via pRep/Cap plasmid and 
were from the same or different serotypes. 
 
Packaged AAV Plasmids 
AAV2/5-F4/80 virus AAV-F4/80-eGFP 
pAd helper plasmid 
pRep2/Cap5 plasmid 
AAV2/5-CAG-GFP AAV-CAG-eGFP 
pAd helper plasmid  
pRep2/Cap5 plasmid 
AAV2-CAG-yfp AAV-CAG-yfp  
pAd helper 
pRV1 (encodes for Rep2/Cap2 
genes) 
Table 2.5. Plasmids required for triple transfections 
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The triple-transfection of HEK 293 cells was set up as follow: for each confluent T150 flask, 12.5 μg 
of AAV backbone plasmid, 25 μg pAd helper plasmid and 12 μg pRep2/Cap5 plasmid or pRV1 (35) 
were added to 2.4 mL of sterile water in a 15 mL Falcon tube, then 330 μL of 2.5 M CaCl2 was 
added to the mixture. The transfection mixture was filtered through a 0.2 μm syringe filter into 
another 15 mL Falcon tube and whilst vortexing the solution vigorously, 2.5 mL of 2x HeBs buffer 
(280 mM NaCl, 1.5 mM Na2HPO4, 50 mM HEPES, PH 7.05) was added quickly. The mixture was 
incubated 2 min at room temperature and 5 mL was applied to the corresponding T150 flask. 
Transfected cells were incubated at 37°C/5% CO2. 16 h post-transfection, media was removed and 
replaced with fresh complete DMDM.  
 
2.5.2 AAV purification 
2.5.2.1 HEK 293 cells harvesting 
96 h post-transfection, HEK 293 cells from AAV2/5-F4/80-eGFP and AAV2-CAG-yfp control flasks 
were washed with warm dPBS and harvested with warm 5 mM EDTA in dPBS. Cell were after 
centrifuged at 600 g for 35 min at 4°C, and the pellets resuspended in Tris-NaCl lysis buffer (50 mM 
Tris, 150 mM NaCl at pH 8.4) with vigorous pipetting to release the AAV virions. In order to release 
as many virions as possible from the cells, the samples underwent three freeze and thaw cycles by 
alternating tubes between dry-ice ethanol and 37°C water bath. To determine isolate AAV2/5 
virions released into medium (Vandenberghe et al., 2010), the AAV2/5-F4/80 supernatant was 
centrifuged at 600 g for 35 min at 4°C to remove cell debris. AAV2-CAG-yfp vector control was 
purified from cell lysates only (Vandenberghe et al., 2010). 
Benzonase endonuclease was added to the cell lysates and AAV2/5-F4/80-eGFP culture medium at 
a final concentration of 50U/mL in order to dissociate aggregated AAV particles and digest any 
extraneous DNA before the Iodixanol gradient step. Lysates and culture medium samples were 
incubated at 37°C for 30 min in water bath, and cell debris were removed by centrifugation at 
3000 g for 15 min at 4°C. Samples were stored at -20°C until Iodixanol gradient step. 
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2.5.2.2 Iodixanol gradient 
Four Iodixanol step gradients were used to purify AAV virus from cell lysate or culture medium 
samples. The 15% interface contained 1 M NaCl to destabilize ionic interactions between 
macromolecules. 40% and 25% steps were used to remove contaminants with lower densities 
including empty capsids. 60% interface was used to gather genome containing AAV Virions. Phenol 
red (Sigma-Aldrich, St Louis, MO, USA), was added in the upper 25% and lower 60% steps to clearly 
see the steps. Iodixanol solutions were prepared as described in Table 2.5.  
 
Density gradient % Density gradient composition (for 2 gradients) 
15% 4.5 mL of 60% + 13.5 mL  of 1 M NaCl/PBS-MK buffer 
25% 5 mL of 60% + 7 mL of PBS-MK buffer + 30 μl of phenol red 
40% 6.7 mL of 60% + 3.3 mL of PBS-MK buffer 
60% 10 mL of 60% + 45 μl of phenol red 
Table 2.5 Iodixanol density gradient steps composition  
 
The solutions were overlaid in a Beckman ultracentrifuge tube as follows: 60% Iodixanol step (5 
mL), 40% Iodixanol step (5 mL), 25% Iodixanol step(6 mL) and 15% Iodixanol step (9 mL) using  18 
gauge needle (BD, Franklin lakes, NJ, USA) (Figure 2.2). The AAV containing sample was divided 
between four Iodixanol gradients, and cell lysis buffer (50 mM Tris, 150mM NaCl, PH 8.4) was 
added on the top of the sample. Tubes were centrifuged at 48,000 g for 2 h 10 min at 18°C with 
maximum acceleration and deceleration in a Beckman Ti70 rotor on a Beckman ultracentrifuge 
(Beckman Coulter, Indianapolis, USA). Approximately 3 mL of virus were collected from each tube 
using 18 gauge needle attached to a 5 mL syringe (BD, Franklin lakes, NJ, USA ) below (3-5 mm) the 
60% and 40% interface (Figure 2.3). At this stage the collected virus was stored at 4°C prior to 
concentration. 
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Figure 2.2 Iodixanol density gradient steps 
 
 
 
Figure 2.3.  Iodixanol density gradient for the purification of AAV. Gradient steps before 
ultracentrifugation (A). The gradient was established from four different densities in Beckman 
ultracentrifuge tubes, using an 18-gauge needle. The gradient included a 15% step containing 1 M 
NaCl to destabilize ionic interactions between macromolecules, 40% and 25% layers allowing the 
removal of contaminants with lower densities including empty capsids and 60% interface gathers 
genome containing AAV Virions. To distinguish between the steps, phenol red was added to the 
25% and 60% steps. After centrifugation (tube B), the AAVs were collected from each tube 3-5mm 
below the 60% and 40% interface (see arrow in tube B) using an 18-gauge needle and syringe 
(Zolotukhin et al., 1999). 
 
A B 
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2.5.2.3 Purified AAV samples concentration  
Samples were concentrated at 3000 g at 4°C for 30-45 min using Vivaspin® 4 centrifugal 
concentrator (Vivaproducts, MA, USA). Three cycles of centrifugation have been performed for 
each sample; in the first  cycle the sample was spun down to 250 μl-500 μl, resuspended with 4 mL 
of 1x dPBS+ 1 mM MgCl2  to prevent virus from aggregation and spun again to as small volume as 
possible. Samples were removed from the concentrator to a sterile microcentrifuge tube and the 
concentrator was rinsed with 250 μl of dPBS+ 1 mM MgCl2 and transferred to the same centrifuge 
tube. Concentrated samples were passed through a 13 mm 0.2 μm syringe filter (JetBioFil, 
Guangzhou, China) and stored at 4°C for short term storage (less than a month) or at -80°C for long 
term storage. 
 
2.5.3 AAV stocks Titering 
2.5.3.1 Total genome copies quantification  
Genome copies of the purified AAV2/5-F4/80 and AAV2 control stocks were titered using QuickTiter 
AAV quantification kit (Cell Biolabs- INC, Israel). Eleven AAV DNA standards were used in the assay: 
10 μg/mL, 5 μg/mL, 2.5 μg/mL, 1.25 μg/mL, 0.625 μg/mL, 0.313 μg/mL, 0.156 μg/mL, 0.078 μg/mL, 
0.039 μg/mL, 0.020 μg/mL, 0.010 μg/mL and 0 μg/mL as the blank. 13.5 μL of each purified AAV 
sample was added to 1.5 μL of 10X QuickTiter™ Solution C containing beads that capture the virus 
capsid and incubated 1 h at 75°C to denature the capsid and release viral DNA. A non-heated 
reaction of each sample was used as a control. Standards, samples and controls were transferred 
to a 96-well plate in duplicates.  90 μL of freshly prepared 1X CyQuant® GR Dye which labels viral 
nucleic acid was added to each well. The relative fluorescence unit (RFU) was calculated for each 
sample using Enspire 2300 fluorescence at 480/520 nm. To calculate the Net RFU we used the 
following formula:   
 
Net RFU = RFU (viral sample) – RFU (non-heated) control sample 
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2.5.3.2 Single-Cell Fluorescent Assay 
In addition to the total genome copies quantification assay, a single-cell fluorescent assay was 
performed to titer infectious AAV2/5-F4/80 and AAV2 control vectors that express GFP and YFP 
respectively. RAW cells and HEK 293 cells were transduced each in triplicates in a 24-well plate 
with serial volumes (5 μl, 10 μl, 15 μl, 20 μl, 40 μl) of AAV2/5-F4/80 virus or AAV2 control 
respectively. On day 5, fluorescent cells were visually scored and number of infectious units was 
calculated for each AAV serotype following the formula below: 
X (Infectious units/mL) =      number of transduced cells x 1000 μL 
                                      Volume of AAV vector (μL) 
 
2.5.3.3 AAV capsid protein detection 
To detect the encapsulated AAV2/5-F4/80-GFP and AAV2-CAG-YFP virions in the purified samples, 
SDS-PAGE electrophoresis was performed to identify the three capsid proteins of the virus VP1, 
VP2 and VP3. Protein concentrations were determined by Bradford assay (Biorad®) and 5 μg of 
each sample was mixed to 2.5 μl of NuPAGE LDS sample buffer (x4) and 1 μl of NuPAGE sample 
reducing agent (x10). Samples were heated for 10 min at 70°C.  The gel chamber was loaded with 
800 mL of MOPS buffer and 500 μl of NuPAGE antioxidant. 1.5 μL of protein size marker was 
loaded onto the first well and 10 μl of AAV2 vector control (cell lysate),  AAV2/5 (cell lysates and 
culture medium) were loaded onto well 2, 3 and 4 respectively. SDS-PAGE gel was run for 45 min 
at 200 V (400mA). 
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CHAPTER 3  
 
REPROGRAMMING OF RECOMBINANT AAV INTO A MICROGLIA SPECIFIC VECTOR 
 
3.1 Introduction 
Using recombinant AAV-gene delivery based technology to target a specific mammalian cell 
without affecting other neighbouring cells can be very challenging if the transgene is under control 
of a non-discriminatory promoter such as CMV. Additionally, CMV and other non-specific 
promoters can be silenced in the mammalian host cell in vivo, and silencing is believed to occur by 
methylation resulting in instable transgene expression (Prosch et al, 1996). This issue has been 
overcome through the use of CMV hybrid promoters such as CMV/chicken β-actin hybrid (CAG) in 
Niwa at al. study, in which CAG promoter achieved a long-term expression of GFP in the 
hippocampal pyramidal neurones lasting for at least 7 months (Niwa et al., 1991). However, the 
AAV expression driven by CAG was not exclusive to hippocampal pyramidal neurones since GFP 
fluorescence was detected also in the areas that innervate hippocampus (i.e. the medial septum 
and the entorhinal cortex neurones) (Peel and Klein, 2000). 
Since the first use of a cell-specific promoter in the Klein et al. study, where the brain-derived 
neurotrophic factor (BDNF) was controlled and stabilised in the hippocampus by using the Neuron-
Specific Enolase (NSE) promoter (Klein et al., 1998), the hurdle of delivering a transgene of interest 
to the target cell and affecting neighbouring cells in the CNS has been surmounted. In addition, it 
was suggested that promoters that are derived from elements of the target cell can induce 
synthesis of transgene proteins that result in concentrations closer to physiological levels (Peel and 
Klein, 2000). 
Therefore, the aim of this research was to construct a recombinant AAV vector that targets 
resident macrophage cells in the brain (i.e. microglia). To achieve this aim, the F4/80 promoter was 
inserted into an AAV-eGFP vector backbone, and the specificity of this recombinant AAV vector for 
macrophages was investigated.  
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3.2 Results 
3.2.1 Construction of AAV-F4/80-eGFP   
F4/80 promoter sequence was amplified from the pEZX-PG02 plasmid (see map in appendix 1B) by 
polymerase chain reaction (PCR) using customized primers containing restriction sites SalI and 
NheI (Table 2.4). After cleaving the PCR product with SalI and NheI to create complementary ends, 
the F4/80 promoter was ligated to the AAV-eGFP shuttle vector using T4 DNA Ligase at 0.1 units at 
1:3 ratio of vector: insert. Following the transformation of DH5α competent cells with the ligation 
product and culture overnight, a colony PCR was carried out using F4/80 primers to check that the 
promoter was successfully ligated to the AAV-eGFP backbone. PCR screening of thirty colonies of 
transformed E.coli with ligation products (Figure 3.1A) confirmed insertion of F4/80 promoter into 
the AAV-GFP vector in eleven colonies. However, since the negative control C2, which contained 
PCR reagent and F4/80 promoter insert primers only, showed a contamination with F4/80 insert 
sequence, another colony PCR was performed  to double check the insertion of the promoter into 
the vector, using different stocks of MyTaq™ Mix and primers, which showed no contamination 
and confirmed the result (Figure 3.1B).  
A double digestion of the newly constructed AAV-F4/80-eGFP clone was performed using SalI (cuts 
at 911 bp) and NheI (cuts at 2279 bp) generated a 6653 bp band and 1368 bp band, corresponding 
to the vector AAV-GFP backbone and the F4/80 promoter sequence respectively (Figure 3.2A).  
Once the positive clone was identified, the integrity of the inverted terminal repeats (ITRs), which 
can recombine during amplification process, was checked by performing a restriction digestion at 
the ITRs sites. XmaI and MscI enzymes cut at both ITRs regions (see chapter 2, figure 2.1 for 
restriction sites); therefore to verify if these viral sequences were still intact, a single restriction 
digest of the plasmid was performed using these enzymes. The band sizes that were expected to 
be generated from each restriction enzyme were present (Figure 3.2B) confirming the integrity of 
both ITRs in the newly constructed AAV-F4/80-GFP vector. 
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Figure 3.1 PCR screening of transformed E.coli colonies. A) Thirty colonies of E. coli transformed 
with the ligation were added each to a PCR tube with MyTaq™ Mix and the following customized 
F4/80 promoter primers : Forward 5’CCCCGTCGACATTACAGGTGCCTAACACCA3’and Reverse 
5’CCCCGCTAGCTATGCTGTAGTTCTGTCATT3’ (20μM final concentration each). The PCR reaction 
was run as described in Chapter 2, Section 2.1.4.5. The inserted F4/80 promoter has been 
identified in 13 out of 30 colonies (highlighted by yellow arrows).  C1 was a positive control 
containing the MyTaq™ Mix, primers and the F4/80 promoter plasmid source pEZX-PG02 to 
monitor the primers’ efficacy. C2 was a negative control containing the MyTaq™ Mix and insert 
primers only in order to check for reagents contamination with F4/80 insert sequence. The 
presence of a thin band corresponding to F4/80 insert size in the C2 control was related to the 
reagents contamination. B) Another colony PCR was performed with MyTaq™ Mix reagent and 
insert primers obtained from different stocks to verify the result obtained in gel A. Three colonies 
from the 13 colonies identified to have F4/80 promoter inserted in gel A, were chosen to run in 
lanes 5,6 and 7. The C2 negative control contained PCR reagents from different stocks showed no 
contamination and the bands obtained in Lines 5, 6 and 7 represented amplified F4/80 insert.  
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Figure 3.2 AAV-F4/80-eGFP clone confirmation. A) The constructed AAV-F4/80-eGFP clone 
digested with SaII (at 911) and NheI (at 2279) restriction enzymes and the uncut clone were run in 
a 0.9% low melting point agarose gel in TAE buffer (shown between yellow brackets). B) A single 
digestion of AAV-F4/80-GFP plasmid was performed to check ITRs integrity. Following XmaI 
digestion four bands were generated including: 4686 bp, 1578 bp, 1104 bp and 659 bp (shown 
with yellow arrows).Three bands were generated following MscI digestion: a 3503 bp, a 3230 bp 
and a 1288 bp band (shown with blue arrows). The band shadow under the 3230 bp band is an 
artefact. 
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Figure 3.3 AAV-F4/80-eGFP vector plasmid map. The newly constructed AAV-F4/80-eGFP plasmid 
contained the F4/80 promoter inserted at SaII (911 bp) and NheI (943 bp) restriction sites, driving 
the expression of enhanced green fluorescent protein eGFP. eGFP expression was further 
enhanced by Internal Ribosome Entry site element (IRES), this element is useful in gene delivery to 
coordinate and efficiently express two genes that are under control of same promoter in a single 
vector. All plasmid genes were flanked by the AAV two ITRs from serotype 2. The vector backbone 
is an Invitrogen pFastBac ™ plasmid. 
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3.2.2 The F4/80 promoter drove eGFP expression in RAW 264.7 cells but not in 
HEK 293 cells  
Once the AAV-F4/80-eGFP vector was constructed, we tested whether the F4/80 promoter would 
regulate the expression of eGFP in a macrophage-specific manner compared to the CAG promoter. 
This promoter is a non-discriminatory promoter which is a combination of the cytomegalovirus 
(CMV) early enhancer element and chicken β-actin promoter, and is widely expressed in eukaryotic 
cells. Thus, we compared the expression of eGFP by the HEK 293 (human embryonic kidney) and 
RAW 264.7 (macrophage) cell lines transfected with AAV-F4/80-eGFP or AAV-CAG-eGFP. 
To optimize the transfection efficiency, RAW 264.7 and HEK 293 cells were serially transfected 
with increasing concentrations of AAV-CAG-eGFP plasmid in a 24-well plate to determine the 
lowest amount of the plasmid that would transfect the cells efficiently. Cells treated with 
Lipofectamine only were used as a negative control to assess background fluorescence. Cells were 
analysed 16-24 h post-transfection, using a fluorescence microscope to visualize GFP expression 
before being harvested for flow cytometry analysis. In RAW 264.7 cells, eGFP expression was 
observed by fluorescent microscope under the control of both F4/80 and CAG promoters (Figure 
3.4). When the level of eGFP expression was measured by flow cytometry, the mean fluorescence 
intensity obtained from 1 μg or 2 μg of AAV-F4/80-eGFP plasmid DNA was similar to that of AAV-
CAG-eGFP and was higher than the Lipofectamine only control (Figure 3.5B). Furthermore, a 
similar percentage of cells were eGFP positive with both F4/80 and CAG promoters in RAW 264.7 
cells (Figure 3.6). Thus, although the level of expression was modest, this finding confirms the 
ability of the F4/80 promoter to drive gene expression in macrophages.  
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Figure 3.4 eGFP was expressed under both F4/80 and CAG promoters in RAW 264.7 cells. On 
approaching confluence, plated RAW 264.7 Cells in complete DMEM media in a 24-well plate, were 
transfected with 1 μg or 2 μg of AAV-CAG-eGFP or AAV-F4/80-eGFP plasmids using 4ul of 
Lipofectamine LTX plus reagent (Invitrogen,) according to the protocol described in chapter 2, 
section 2.2.2 and incubated overnight at 37°C in 5% CO2. Cells containing lipofectamine only were 
used as a control to check fluorescence background. After 24h, cells were analysed under 
fluorescent microscope (Olympus 1x 51) to visualize eGFP expression from each vector plasmid. 
The up left image shows the RAW cells confluency at the time of transfection. EGFP fluorescence 
was seen in RAW cells transfected with AAV-F4/80 (bottom right image) or AAV-CAG plasmids 
(bottom left image). Scale bar: 200 μM, magnification = 10 x. 
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Figure 3.5 Similar eGFP expression was found with the AAV-CAG-eGFP or AAV-F4/80-eGFP 
plasmids. RAW 264.7 cells were washed and harvested at 24 h post-transfection with warm dPBS. 
After centrifugation at 300 g for 5 min, the cell pellets were resuspended with ice-cold FACS buffer, 
and samples were transferred to FACS tubes for analysis. Live cells were gated based on forward 
scatter (FSC-A) and side scatter (SSC-A) of untransfected  RAW cells. All single cells have been 
clustered diagonally  to exclude dead cells,  doublets and clumps (A). GFP expression in RAW cells 
was determined by flow cytometry and shown as the geometric mean fluorescence (B).  
Doublets  
De
ad 
cell
s 
an
d 
clu
mp
s 
Doublets  
RAW CELLS 
GFP+ GFP+ 
  Page 58 
 
 
 
 
 
Figure 3.6 eGFP expression percentage was equivalent under control of both promoters.  
RAW cells were washed and harvested at 24 h post-transfection with warm dPBS. After 
centrifugation at 300 g for 5 min, the cell pellets were resuspended with ice-cold FACS buffer, and 
samples were transferred to FACS tubes for analysis. Live cells were gated as shown in Figure 3.5 
and the % of eGFP positive cells determined. EGFP expression in transfected RAW cells with AAV-
F4/80-eGFP or AAV-CAG-eGFP promoters were compared each against Lipo only control using one 
way ANOVA with Sidak’s post hoc test. Shown are the means and SD of duplicates wells from one 
representative experiment of 3 replicates. * P < 0.05.  
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In HEK 293 cells, fluorescence microscopy indicated a high expression of eGFP under control of 
CAG promoter while only a few cells expressed eGFP under control of the F4/80 promoter (Figure 
3.7). Flow cytometric analysis of live HEK 293 cells was consistent with the fluorescence 
microscopy findings (Figure 3.8) and the reporter gene expression was not detected in HEK cells 
despite the high amount of AAV-F4/80 plasmid used (Figure 3.9). Comparing the F4/80 promoter 
activity with both cell lines, we can see a shift in eGFP expression in RAW 264.7 cells which 
indicates that the promoter is active only in macrophages cell line and not in HEK cells (Figure 
3.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 EGFP expression was extremely low under F4/80 promoter control in HEK 293.  
Twenty-four hours prior to transfection, HEK 293 cells were plated out in a 24-well plate at 0.4 x 
10⁶ cells/well in complete DMEM. Cells were transfected at 70% confluency (upper left) with 1 μg 
or 2 μg of AAV-F4/80-eGFP shuttle plasmid or AAV-CAG-eGFP. Transfected cells were incubated for 
16-24 h at 37°C in 5% CO₂, and eGFP fluorescence in transfected cells was evaluated under 
fluorescence microscopy (magnification = 10x) and was compared against untransfected cells (Lipo 
only). 
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Figure 3.8 Increasing the amount of AAV-F4/80-eGFP plasmid did not boost GFP expression in 
HEK 293. HEK 293 cells were harvested 24 h post-transfection to quantify eGFP fluorescence via 
FACS analysis using same protocol described previously (Figure 3.5). All single cells have been 
clustered diagonally  to exclude dead cells,  doublets and clumps (A). 
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Figure 3.9 EGFP expression was not induced under F4/80 promoter control in HEK 293. EGFP 
expression was compared in HEK 293 cells transfected with AAV-CAG-eGFP, AAV-F4.80-eGFP, or 
Lipo only control using one way ANOVA with Sidak’s post hoc test. Shown are the means and SD of 
duplicate wells from one representative experiment of three replicates. * P < 0.05.  
 
 
 
Figure 3.10 F4/80 Vs CAG in HEK and RAW cells. The significance of GFP expression was compared 
under each promoter in both cell lines using unpaired t test with Welch’s correction of one-way 
ANOVA test. * P < 0.05. 
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3.2.3 The F4/80 promoter did not drive eGFP expression in HepG2 and 1A9 cell 
lines 
To confirm this finding, we transfected other human cell lines including the human hepatocytes 
cell line (HepG2), and human ovarian carcinoma cell line (1A9). The transfection protocol used was 
the same as described previously, and eGFP expression was assessed using fluorescence 
microscopy 16-24 h post-transfection. Fluorescence microscopy indicated the CAG promoter was 
active in both HepG02 (Figure 3.11) and IA9 cell lines (Figure 3.12); however, no GFP expression 
was observed when the AAV-F4/80-eGFP plasmid was used in either cell line.  This result further 
suggests that the F4/80 promoter is selective for macrophages.       
 
 
 
Figure 3.11 F4/80 promoter did not induce eGFP expression in HepG2 cells.  
HepG2 cells were plated out in a 24-well plate at 0.4 x 10⁶ cells/well and maintained in complete 
DMEM media prior to transfection. Once confluency reached 70%, cells were transfected with 1 μg 
or 2 μg of AAV-F4/80-eGFP or AAV-CAG-eGFP plasmid. eGFP was expressed under CAG control 
(bottom left image) and no expression was detected under control of F4/80 promoter (bottom 
right image). Scale bar: 200 μm, magnification = 10x.  
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Figure 3.12 F4/80 promoter did not induce eGFP expression in 1A9 cells.  
1A9 cells were maintained in complete DMEM and transfected using the same protocol as 
described in Figure 3.11. After 16-24h, eGFP fluorescence was visualized by fluorescent 
microscopy. eGFP was not expressed in cells transfected with AAV-F4/80-eGFP plasmid (bottom 
right image) compared with AAV-CAG-eGFP (bottom left image) where eGFP was expressed. Scale 
bar: 200 μm, magnification = 10x.  
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3.3 Discussion 
3.3.1 AAV-F4/80 shuttle vector construction 
Prior to investigating the role of microglia in neurodegeneration, we first aimed to create a 
microglia-specific recombinant AAV vector. We constructed our AAV vector by inserting the F4/80 
promoter into an empty AAV shuttle vector containing the reporter gene eGFP, which would help 
monitor the promoter activity as well as identifying transfected cells. An IRES sequence was 
located between the F4/80 promoter and eGFP gene. This sequence has a role in coordinating 
both the expression of a transgene of interest and reporter gene. Both the F4/80 promoter and 
eGFP gene were flanked by two ITRs sequences derived from AAV serotype 2. These viral 
sequences are required for AAV vector replication and packaging (Frase Wright, 2009), and 
represent the only viral-derived DNA present in the packaged recombinant AAV virus. The maximal 
length of inserted DNA that the two ITRs can hold is 4-6kb (Lai et al, 2010). Our newly constructed 
AAV expression cassette contained ~3.4 kb of ITR flanked DNA. A single restriction enzyme 
digestion with MscI and XmaI was performed to check the integrity of both AAV-F4/80 ITRs 
sequences that can recombine during cloning process and amplification. This is an alternative 
method to sequencing as ITRs contain a heparin secondary structure (Chapter 1, figure 1.1A), 
rendering their sequencing very difficult.  
 
3.3.2 F4/80 promoter specificity investigation 
Since no microglia-specific marker has been established yet, we chose to use the macrophage 
F4/80 element as a promoter, which would drive AAV expression exclusively in microglia when the 
AAV particles are injected into the brain. Although F4/80 is expressed on tissue macrophages 
(including peritoneal, liver, splenic, kidney, epidermal, thymis and bone marrow macrophages), 
within the central nervous system in a healthy mouse, F4/80 is expressed specifically on microglial 
cells (Cucchiarini et al, 2003, McKnight and Gordon, 1998).  In addition, it was demonstrated by 
Cucchiarini et al. that F4/80 promoter has a restricted activity to microglia (McKnight, Gordon, 
1998). Their group have evaluated AAV vector expression under control of the three myeloid-
specific elements: CD11, CD68 and murine F4/80 in primary rat microglia and other brain cell 
populations as well as a different lineage of macrophages (mature human lung alveolar 
macrophages). Their results showed a restricted expression of transgene in microglia under F4/80 
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promoter control vis-à-vis other promoters and other cell types. Prior to packaging our 
constructed recombinant AAV-F4/80-eGFP, we wanted to confirm this finding by testing the vector 
in vitro on human cell lines that have not been investigated, including HEK 293, HepG2 and 1A9 
cell lines. Promoter activity was compared in these cell lines against the commonly used 
macrophages cell line RAW 264.7 cells (Hartley et al, 2008).   
We elected to use HEK 293 cells as they are very easy to transfect and are commonly used for 
packaging AAV vectors. Thus we were able to optimize the mammalian cell transfection protocol 
as well as investigate F4/80 promoter specificity. The specificity of our vector was compared 
against an AAV-CAG-eGFP vector control driven by a widely employed non-discriminatory CAG 
promoter (Balakrishnan et al., 2013, 28). The AAV-CAG-eGFP plasmid size was approximately the 
same as the AAV-F4/80-eGFP plasmid (8.3 kb, ~8 kb respectively), and cells were transfected with 
serial amounts of AAV-CAG plasmid in order to ascertain the lowest amount of DNA plasmid that 
would transfect the cells efficiently. We found 0.25 μg of AAV-CAG DNA plasmid was sufficient to 
efficiently transfect HEK 293 cells (Appendix 3, figure 3A); however, this amount was not enough 
to achieve a good transfection of RAW 264.7 cells. Instead, 1 μg was required to see a reasonable 
level of eGFP fluorescence in RAW 264.7 cells (Appendix 3, figure 3B).  
In this study we demonstrated that the human F4/80 (EMR1) promoter worked well in the mouse 
macrophages cell line, which was demonstrated by clear expression of eGFP comparable to the 
one obtained under CAG promoter control. The promoter was tested in non-macrophage human 
cell lines including HEK 293, HepG2 and 1A9 and did not show any activity. This result was 
consistent with and complementary to Cucchiarini et al. providing strong evidence that our viral 
tool has a restricted activity to microglia and can be used to investigate the role microglia in neuro-
inflammatory conditions (Cucchiarini et al ,2003).  
 
 
  
  Page 66 
 
CHAPTER 4  
RECOMBINANT AAV2/5 PRODUCTION 
 
4.1 Introduction 
After construction of the recombinant AAV (AAV) vector and verification of its specificity for 
macrophages, we aimed to further confirm its exclusive gene delivery to macrophages in vitro by 
transducing splenocytes, which is a mixed leukocyte population containing macrophages, as well 
as in vivo via a systemic injection. Once confirmed, we could then deliver the AAV2/5 to microglia 
in vivo via a stereotactic injection into mice brain. The most extensively studied AAV serotype and 
the most used in CNS gene delivery is AAV2 (Choi et al., 2005). However, because the capsid of the 
serotype 2 was shown to primarily transduce neurons (Davidson et al., 2000), we replaced the AAV 
capsid 2 with the serotype 5 capsid. This capsid has been shown to have a much broader tropism 
and is capable of selectively infecting microglia when driven by a specific promoter (Cucchiarini et 
al., 2003). In addition, the use of the pseudotype 2/5 will reduce the host immune response and 
stabilize transgene expression compared with AAV2, which is prone to induce local inflammatory 
reactions since 80% of human population is AAV2 seropositive (Choi et al., 2005; Vasileva and 
Jessberger, 2005).  
In order to test the infectivity and specificity of our AAV2/5 virus, the latter needs to be produced. 
The major steps of AAV production include: 1) packaging of the virus in a transitory producer cell, 
2) purifying the AAV particles, and 3) titering the AAV stock. 
For the AAV vector packaging, transient transfection of HEK 293 or HeLa is the most commonly 
used method because it is a flexible and convenient method for pre-clinical studies when a specific 
transgene construct and serotype may need to be tested prior to use in clinical studies (Fraser 
Wright, 2009). In comparison, the baculovirus system, in which recombinant AAV is packaged in 
insect cells, is time consuming and may be suited only to large-scale clinical studies (Virag et al., 
2009; Urabe et al., 2006). We therefore selected the former method to produce our AAV vector of 
interest using HEK 293 cells given that HeLa cells are considered hazarduous to use due to the 
presence of the Human Papilloma Virus 18 sequence (HPV18) (Schwarz et al. 1985).  
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In order to achieve an efficient transient transfection of adherent HEK 293 cells, calcium 
phosphate (CaPO4) precipitation prepared in-house is currently the method of choice in many 
laboratories due to its simplicity (McClure et al., 2011;, Li et al., 2006; Iwata et al., 2013). This 
method is also cost effective compared with commercial cationic lipids reagents such as 
Lipofectamine LTX plus reagent, and although these reagents are very efficient, cost is a limiting 
factor considering the large volume of cultured HEK 293 cells required to produce a scalable 
amount of AAV. Therefore, calcium phosphate method was chosen to transfect our packaging 
plasmids in HEK 293 cells.   
We selected the simplest and most extensively used method in preclinical studies - the triple 
transfection approach (Xiao et al., 1999; McClure et al., 2011). This versatile method requires co-
transfection of three plasmids permitting simultaneous manufacture of different AAV vectors. 
These plasmids are: 1) the expression cassette, 2) Rep/Cap plasmid, and 3) the helper plasmid. The 
expression cassette contains the AAV 145bp inverted terminal repeats (ITRs) flanking the 
transgenes of choice as well as a fluorescent probe such as YFP or GFP to monitor the vector 
pathway and investigate its characteristics. The Rep/Cap plasmid contains replication and capsid 
genes of AAV that are supplied in trans and are necessary to package recombinant AAV. These 
genes could be from the same or different serotype. Finally, the helper plasmid carrys the 
necessary adenovirus genes required for an efficient AAV replication, since the wild type AAV 
needs co-infection with another virus such as adenovirus or Vaccinia virus for an efficient 
production in the host cell (Daya and Berns, 2008). There are four adenovirus helper genes 
required for the AAV production; E2A, VA, E4 which are delivered in trans in a plasmid and E1 is 
supplied in HEK 293 cells. These cells have been transformed with an adenovirus serotype five to 
express the E1 (E1A and E1B) gene (Merten et al., 2005).  
Once assembly of the virus was performed, the next stage in production is to purify the viral 
particles. Purification strategy varies in many laboratories, in some studies they prefer a 
combination of density gradient ultracentrifugation including caesium chloride (CsCl) or iodixanol 
gradient and chromatography (an affinity or ion exchange chromatography depending on the 
serotype of the virus) and in other studies they chose to perform one-step purification, a density 
gradient or a chromatography. Since iodixanol density gradient was adapted by Zolotukhin et al., it 
became the preferred method in many laboratories to purify AAV vectors due to its iso-osmotic 
and inertness properties at all densities Thus, we selected a one-step purification process using 
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Iodixanol density gradient to purify our recombinant AAV2/5-F4/80 vector (Zolotukhin et al., 
1999).  
Following AAV particles purification, viral stocks are titered for use in downstream experiments. 
Commonly used approaches to titer purified AAV vector particles include Western blot analysis 
(Zolotukhin et al., 2002; McClure et al., 2011), SDS-PAGE electrophoresis, viral genome 
quantification by dot blot or qPCR, and AAV infectivity assay. In one viral genome assay 
(QuickTiter™ AAV Quantitation kit), an anti-AAV2 capsid monoclonal antibody is used to identify 
AAV particles of serotype 2. Although this antibody was shown to recognise AAV1 and AAV5 capsid 
proteins as well (Wobus et al., 2000), it is not applicable to all serotypes. SDS-PAGE electrophoresis 
detects the three AAV capsids VP1, VP2 and VP3 and can assess the purity of the stocks; however, 
titering AAV vector stocks via capsids proteins only is not accurate as empty capsids might be 
included in the titer. This assay is commonly used in conjunction with viral genome copies 
quantification as described above or by Dot-blot assay or qPCR (Iwata et al., 2013; Grieger and 
Samulski, 2005; Gonga et al., 2004; Paterna et al., 2000). To investigate AAV particles cells tropism 
and assess their ability to infect cells, an AAV infectivity assay is performed such as single-cell 
fluorescence assay (SCFA) to determine AAV vector infectious titer (Zolotukhin et al., 2002; 
McClure et al., 2011).  
In order to titer our AAV2/5 viral stocks, we elected to perform an SDS-PAGE electrophoresis 
followed by quantification of viral genome copies using QuickTiter™ AAV Quantitation kit and a 
single-cell fluorescent assay. These assays were selected as they provide complementary 
information about the viral genome copy number, viral proteins, infectivity and cellular tropism. 
Therefore, using the approach outlined in Figure 4.1, we aimed to generate 
macrophage/microglia-specific, packaged AAV2/5 to use for further experiments. 
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Figure 4.1.  Recombinant Adeno-Associated virus vector production flow chart  
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4.2 Results 
4.2.1 AAV2/5-F4/80 packaging via HEK 293 transient transfection 
The starting point for generating our AAV-F4/80 pseudotype 2/5 was the calcium phosphate-
mediated transient transfection of HEK 293 cells. The following three plasmids were used: the 
AAV-F4/80 shuttle plasmid, the pAd helper plasmid and the Rep2/Cap5 plasmid. The three 
plasmids were combined at a 1:2:1 molar ratio respectively. Since F4/80 promoter is not active in 
HEK 293 cells, we used our AAV-CAG-eGFP vector control to monitor transfection efficiency by 
tracking eGFP expression as well as AAV production. However, using that control alone was not 
enough to troubleshoot our experiment because we were not able to detect it in downstream 
processes; therefore we decided to use another AAV vector control, AAV-CAG-yfp vector serotype 
2, which has been successfully produced by others using the same protocol. This second control 
vector was a kind gift from Associate Professor Bronwen Connor, University of Auckland.  
To assess the level of transfection, the cells were examined under the fluorescence microscope. 
Twenty-four hours post-transfection, both control constructs, AAV-CAG-yfp and AAV-CAG-eGFP, 
were expressing equivalent amounts of yfp and eGFP, respectively, but the fluorescence levels did 
not reach 50% (Figure 4.2C and E). In contrast, a very low number of fluorescent cells appeared in 
cells transfected with AAV-F4/80 vector, which was expected as the promoter activity has been 
shown to be very low in these cells (Chapter 3, Figure 3.7). In an effort to improve the efficiency of 
transfection, we monitored the pH of all transfection reagents, added them in the order 
recommended by the protocol, and used a low passage of HEK 293 cells. However, these 
adjustments did not improve the transfection efficiency of either AAV vector control.  
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Figure 4.2. HEK 293 cells  transient  transfection.  A) A representative image of HEK 293 before 
transfection (10X magnification). Cells were plated out at 5 x 10⁶ cells/T150 flask and were cultured 
until they reached  80-90% confluency. Three h prior to transfection, complete DMEM media was 
changed and replaced with IMDM media that is high in glucose and suitable for high density cell 
cultures.  . B) A representative image of HEK 293 after triple transfection. Briefly, 12.5 μg of AAV 
backbone plasmid, 25 μg of of pAd helper plasmid and 12 μg of pRep/Cap plasmid were added 
with the CaPO4 mixture to each flask. Sixteen hours post-triple transfection, the medium was 
changed and replaced by complete EMDM with 10% FCS. C-E) Representative images at 24h post-
triple-transfection of AAV-CAG-yfp (C), AAV-F4/80 (D) and AAV-CAG-eGFP (E). Scale bar: 200μM, 
magnification 10x.  
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4.2.2 Purification and Titering of AAVs Virions 
The next step in the production process of the AAVs consisted of extracting and purifying the AAVs 
from transiently transfected HEK 293 cells at 92 hours post-transfection. As with the previous step, 
AAV-CAG-yfp was used to monitor the efficiency of our purification protocol. The transfected HEK 
293 cells were harvested from T150 flasks, and after centrifugation at 600 x g for 35 min at 4°C, cell 
pellets were resuspended in Tris-NaCl lysis buffer (50 mM Tris, 150 mM NaCl at pH 8.4). In order to 
release as many virions as possible from the cells, samples underwent a vigorous pipetting 
followed by three freeze and thaw cycles. To determine if the AAV2/5 virions were released into 
medium (H. Vandenberghe et al., 2010), culture medium of the AAV2/5-F4/80 flask was also 
centrifuged at 600 x g for 35 min at 4°C. The AAV-CAG-yfp vector control that is a serotype 2 was 
purified from cell lysates only (H. Vandenberghe et al., 2010). 
Both cell lysate and culture medium samples were then treated with benzonase endonuclease to 
eliminate any extraneous DNA at a final concentration of 50 U/mL and incubated at 37°C for 30 
min in a water bath. Cell debris from the cell lysate was removed by centrifugation at 3000 x g for 
15 min at 4°C and this supernatant as well as the culture medium containing any released AAV 
virions were stored at 4°C for downstream processing.  
The vector-containing supernatant of each virus type was divided between four Iodixanol 
gradients in ultracentrifuge tubes (Figure 4.3). After an ultracentrifugation at 48,000 x g for 130 
min at 18°C, 3-4 mL of virus were collected at 3-5 mm below the interface between the 60% and 
40% Iodixanol layers (shown by an arrow in Figure 2.3B, section 2.5.2.2, chapter 2).  
 
4.2.2.1 Purified AAV stocks contained high amounts of nucleic acid 
Prior to titering, samples were concentrated to a smaller volume using a Vivaspin® 4 centrifugal 
concentrator. We began titering our AAVs stocks by measuring the genome total copies in each 
sample using QuickTiter AAV quantification protocol (Chapter 2, section 2.5.3.1). In this method, 
AAV particles were captured by beads via their capsid and heated at 75°C for one hour to denature 
capsid proteins and release viral DNA. A non-heated sample was used as a control. AAV2 viral DNA 
standards were used in the assay to obtain a standard curve in order to get AAVs DNA 
concentration in ng/μL (Figure 4.4).  
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The relative fluorescence unit (RFU) was calculated for each sample using Enspire 2300 
fluorescence at 480/520 nm filter set. The result shown in Table 4.1 indicated that the RFU of all 
samples controls (non-heated samples) was higher than that of heated samples. This result 
suggested that the high amount of DNA found in the non-heated sample purified from culture 
medium might correspond to the DNA derived from packaging plasmids that have not been taken 
up by HEK cells. The host DNA may be also present in the medium-derived AAV stock as well. 
Whereas, in the samples purified from cell lysate, the high RFU of their controls might be due to a 
high amount of cellular DNA and non-packaged viral DNA. This result clearly indicated that 
benzonase treatment of samples before purification was not sufficient to eliminate extraneous 
DNA. Therefore, another treatment must be performed at the post-purification step to completely 
remove unwanted nucleic acids. Because net RFU was negative, we were not able to calculate the 
titre of AAV vector stocks using this method. 
 
 
Table 4.1. Control RFU is higher than the sample RFU. Purified samples (cell lysates and culture 
medium) were prepared as per manufacturer instructions. Briefly, AAV DNA standards were used 
to create a standard curve (Figure 4.3). 13.5 μL of each purified AAV sample was added to 1.5 μL of 
10X QuickTiter™ Solution C containing beads that capture the virus. Samples were incubated one 
hour at 75°C to denature the capsid and release viral DNA. A non-heated reaction of each sample 
was used as a control. Standards, samples and controls were transferred to a 96-well plate in 
duplicates.  90 μL of freshly prepared 1X CyQuant® GR Dye which labels nucleic acid was added to 
each well. To calculate the net RFU we use the following formula: net RFU = (RFU of viral sample) – 
(RFU of non-heated control sample). 
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Figure 4.3.  AAV2 DNA Standard Curve 
 
4.2.2.2 The three capsid proteins of AAV2/5 virus were not detectable in SDS-
PAGE 
SDS-PAGE was performed to analyse the AAV stock purity and to detect the three VP proteins of 
AAV virions capsid: VP1 (82 kDa), VP2 (72 kDa), VP3 (62 kDa). These proteins are present in a 
1:1:10 molar ratio, respectively (S. Steinbach et al., 1997). SDS-PAGE gel analysis indicated high 
cellular protein contamination in both AAV2 control and AAV2/5 stocks purified from cell lysate 
and culture medium (Figure 4.5). The contamination was much higher in the AAV2/5 stock 
obtained from culture medium. VP protein capsids were not distinguishable from other proteins in 
the gel indicating a poor recovery of the vectors. The poor recovery might be due to a low vector 
production and/or failure in collecting most of the particles from Iodixanol gradient fraction due to 
a poor performance. Although SDS-PAGE result allowed us to assess the quality, this analysis was 
not efficient in detecting the few capsid proteins that were present in the stocks. Therefore, a 
Western blot analysis might be considered when AAV titer is very low.    
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Figure 4.4.  AAV vector stocks were highly contaminated with cellular material. The protein 
concentration of each stock was determined by Bradford assay. Five μg of each sample was mixed 
with 2.5 μL of NuPAGE LDS sample buffer (x4) and 1 μL of NuPAGE sample reducing agent (x10). 
Samples were heated for 10 min at 70°C.  The gel chamber was loaded with 800 mL of 1x MOPS 
buffer and 500 μL of NuPAGE antioxidant. 1.5 μL of protein size marker was loaded onto the first 
well and 10 μL of AAV2 vector control cell lysate, AAV2/5 cell lysate (CL) and culture medium (CM) 
were loaded onto well 2, 3 and 4, respectively. SDS-PAGE gel was run at 200V (400mA) for 45 min 
and stained with Coomassie Blue to visualize the proteins. 
 
4.2.2.3 Low infectious titer of AAV2 control and AAV2/5-F4/80 particles 
Performing an infectious titer is crucial to assess the potency of the AAV vector stock that could be 
affected during construction, purification or storage. The common protocol used for this assay is to 
transduce HEK 293 or HeLa cells, when the viral vector is driven by a general promoter, with serial 
dilutions of AAV vector with or without helper adenovirus. Infected cells are visually scored via a 
fluorescent probe using a fluorescence microscope and the titer is calculated according to the 
dilution factor (Zolotukhin et al., 1999; McClure et al., 2011). Because the infection process is very 
slow when AAV vector is transduced without helper adenovirus, transgene expression is assessed 
commonly from day five. Some laboratories prefer co-infecting cells with helper adenovirus to 
enhance AAV vector sensitivity (Zolotukhin et al., 1999; Bartlett et al., 2000; Xiao et al., 1998). 
However, we believe that co-infecting cells with adenovirus is not relevant for this situation since 
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the purpose of the assay is to test the potency of the viral vector to transduce cells alone and if it 
does, to determine how long it takes for the cells to express the transgene of interest.     
We implemented an infectivity assay as described previously with few changes (Zolotukhin et al., 
1999). HEK 293 cells were transduced via AAV-CAG-yfp virus control; however, due to the low 
activity of F4/80 promoter in HEK 293 cells (Chapter 3, Figure 3.7), we transduced RAW 264.7 cells 
with the AAV2/5-F4/80 virus purified from cell lysate or from culture medium. Because we were 
not able to detect any VP proteins in SDS-PAGE gel, we did not infect cells with serial dilutions of 
stocks as described in the common protocol, instead we infected cells with serial volumes starting 
from 5 μL to 80 μL to increase chances in detecting any packaged AAV virus. From 24 hours post-
infection, fluorescent cells were monitored under the fluorescence microscope and have been 
scored five days later to determine the infectious titer using the following formula:  
Infectious units/mL  =      Number of transduced cells x 1000 μL 
                                                                                  Volume of AAV vector (μL)     
Fluorescence microscope analysis of infected RAW 264.7 cells with our AAV2/5-F4/80 vector, 
isolated from both culture lysate and culture medium, indicated the presence of fluorescent cells 
in all wells containing the AAV. This result confirmed the presence of packaged AAV2/5-F4/80 
vector in both cell lysate and culture medium stocks. However, the number of infected cells was 
extremely low and did not exceed 15 units per 40 μL of cell lysate stock (Figure 4.6). Thus the 
infectious titer was 375 units per mL which was extremely low compared to the reported titers of 
6 x 10⁹ IU/mL (McClure et al., 2011) and 1.1 x 10¹¹ IU/mL (Zolotukhin et al., 1999). We checked the 
plates 10 days and 15 days later to see if the number of infected cells would increase with time 
since AAV vector has such a slow infection process in absence of helper adenovirus, but the 
number did not increase.  
The low infectious titer of our AAV virus may be due to the low tropism of the capsid 5 for 
macrophages or to the potency of the vector in infecting cells that has been deteriorated during 
purification or storage. However, given that we obtained approximately the same infectious titer 
of the AAV2 vector control in HEK 293 cells (750 IU/mL; Figure 4.6) and the three capsid proteins 
were undetectable by SDS-PAGE, we believe that the low infectious titer was caused by a poor 
recovery of AAV virus from the production process.  
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 Figure 4.5. Few RAW 264.7 cells were infected with the packaged AAV2/5-F4/80 virus.  Images of 
RAW 264.7 cells infected with purified AAV2/5-F4/80 virus. Non-infected RAW 264.7 cells have 
been used as a control. Cells have been plated out at 0.6 x 10⁵ in a 48 well plate and cultured until 
they reached 80% confluency after which cells were infected with serial volumes of the AAV 
vectors: 5 μL, 10 μL, 20 μL, 40 μL, 60 μL, 80 μL without helper adenovirus. Plates were incubated at 
37°C in a 5% CO2 atmosphere, and at 24h post-infection, the presence of infected cells expressing 
eGFP was observed by fluorescent microscope in all wells containing virus. Scale bar: 200 μm, 
Magnification 10x. 
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Figure 4.6. Few HEK 293 cells were infected by the AAV2 virus control. Fluorescent microscope 
images of HEK 293 cells infected with the AAV2 vector control using same protocol described in 
Figure 4.6, which indicated presence of packaged virus in the stock. Scale bar: 200 μm, 
magnification 10x. 
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4.3 Discussion 
Although AAV vectors have been shown to be very successful candidates in gene delivery into 
mammalian cells due to their excellent safety profile and long term stability in animal models 
(Bishop et al., 2008; Kaplit et al., 1994; Fana, 2008), their production is still a challenge and may 
affect downstream experiments, when recombinant AAV vector generated stock is not consistent 
in terms of purity and quantity. We aimed in this project to produce our AAV2/5-F4/80 virus to use 
in our experiments but we failed to produce a sufficient amount that would enable us to test the 
vector in vivo and in vitro. In order to troubleshoot our method of production, each step will be 
discussed in detail and alternative approaches proposed to optimize the protocol for future 
experiments. Overall, the main production steps that can affect vector yield include: the transient 
transfection, AAV packaging and AAV purification, and thus it is highly likely that optimization of 
one or more of these steps in our protocol is required to enable efficient AAV production.  
 
4.3.1 Transient Transfection 
Transient transfection of the HEK 293 cell line with the AAV packaging plasmid represents the first 
challenge in AAV vectors production. While the calcium phosphate method is very efficient when 
optimized, generating more than 10⁵ vector genome per cell (Fraser Wright, 2009), it is still a very 
sensitive procedure and needs a consistent performance in order to transfect up to 90% of HEK 
293 cells. In our experimentation, the HEK 293 transient transfection did not reach 50% according 
to fluorescent intensity of both AAV controls used AAV-CAG-yfp and AAV-CAG-eGFP (Figure 4.1). 
This was certainly due to the transfection reagent characteristics as it has been shown earlier that 
a failure in maintaining transfection reagents at room temperature and at required pH at the time 
of transfection dramatically affects AAV production (Fraser Wright, 2009). Furthermore, the quality 
of the HEK 293 cell line affects transfection efficacy and transfection can only be performed at 
their optimal receptive conditions: maintaining them at their exponential growth, plating them at 
low passage (lower than 30 passages) the day before transfection and transfecting them when 
they reach 80% confluency will increase DNA uptake by the cells.  
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4.3.2 AAV Packaging 
Recombinant AAV vector packaging using the triple-transfection protocol is another limitation in 
the production process. Despite the AAV standard genome size, which does not exceed the limited 
capacity of the capsid, it was demonstrated previously by Grimm et al. that when the packaging 
efficacies of both WT AAV and recombinant AAV where compared, the chances in producing 
empty capsids were very high during the packaging process of recombinant AAV vectors (Grimm et 
al., 1999). The empty capsids appear when the threshold of assembled capsids that are ready to 
package recombinant genomes is not reached due to the overexpression of VP proteins (Grimm et 
al., 1999). Furthermore, Li et al. showed that Rep78/68 protein overexpression affects AAV vector 
yield as well by decreasing AAV DNA replication efficiency and by lowering capsid proteins 
synthesis (Li et al., 1997). Thus the amount of Rep/Cap plasmid supplied in trans needs to be 
optimized for an efficient AAV production. However, in our protocol, the amounts of AAV 
packaging plasmids have been already optimized previously and generated a good titer (McClure 
et al., 2011). Another impediment in the AAV vector packaging was the generation of AAV particles 
that contain DNA sequences other than the vector genome such as pseudo-wild type AAV, residual 
plasmids and host cell DNA which decreases AAV infectivity and induces unwanted immune 
responses (Allen et al, 1997; Wang et al., 1998; Chadeuf et al., 2005).  
Another major obstacle known to dramatically affect AAV production yield is the timing and 
process of harvesting the AAV from the transfected HEK 293 cells. The first challenge in this step is 
to determine the best time to harvest the packaged AAV. Since the time of virions release into the 
culture medium is unknown, the reported harvesting time varies between 60-120 hours in most 
laboratories (Vandenberghe et al., 2010). This might affect AAV vector production yield if the cells 
are harvested after the release of virus into the culture medium since all AAV protocols collect 
virus from cell fractions only. It has been demonstrated by Vandenberghe et al. that not all 
serotypes remain in the cell after their production as the AAV2 vector does, and that release of 
packaged viruses into the culture medium is serotype dependent (Vandenberghe et al., 2010). In 
their study, while AAV2 and AAV6 were shown to be strongly associated with the cell via the 
heparin-binding motif after virus production, the AAV5 on the other hand was found mostly in 
culture medium (Vandenberghe et al., 2010). In order to verify this finding, we collected our 
AAV2/5 vector from both cell fractions and culture medium; however we found approximately the 
same infectious titer in both samples (Figure 4.6). Therefore, despite the insignificant titer of 
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AAV2/5, collection of AAV with capsid of serotype 5 from both sources should be taken into 
consideration in order to increase vector yield once the production process has been optimized.  
Another step that requires optimization is the lysis of the AAV-containing HEK 293 cells to release 
as many virions as possible. In our previous tests when we were lysing cells using a lysis buffer as 
described by McClure et al. protocol (McClure et al., 2011); we were unable to detect virions in the 
crude cell lysates and in purified AAV stocks. However, we found that combination of lysis buffer 
with thorough pipetting and three freeze/thaw cycles was sufficient to detect packaged viruses 
using the infectivity assay. Furthermore, formation of aggregates caused by non-specific proteins 
interactions may decrease the production yield when the virus is not efficiently separated from 
other proteins. Thus, treatment of the samples with an ionic detergent such as sodium 
deoxycholate at 0.5% final concentration might be considered to disturb and dissociate proteins 
interactions and prevent aggregates formation.  
 
4.3.3 AAV Purification 
The last step in our AAV production process is Iodixanol density gradient ultracentrifugation 
followed by virions concentration and filtering. We strongly believe that the majority of the AAV 
vector that has been packaged was lost during this stage of purification. The SDS-PAGE result 
(Figure 4.5) indicated that the iodixanol-purified AAV stocks were highly contaminated with 
cellular proteins and the three AAV capsid proteins (VP1, VP2 and VP3) were undetectable. This 
result suggested that the collection of AAV fractions from a discontinuous gradient was not 
accurate and were collected from the interface where most of the cellular proteins migrate and 
only a low amount of AAV was present (Zolotukhin et al., 1999). To confirm this hypothesis, we 
compared our finding with those described by Zolotukhin et al. (Zolotukhin et al., 1999), where an 
AAV vector was similarly purified from crude lysate using an Iodixanol density gradient (Figure 4.8). 
It was demonstrated, by collection of different fractions of AAV virus from different densities 
including; 60%-40% interface (lane 5), 40% density (lanes 6 and 7) and 40%-25% interface (data not 
shown) that fractions 6 and 7 obtained within 40% density were highly contaminated with cellular 
proteins comparing with fractions obtained from the interface 60%-40%.   
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Figure 4.7. Zolotukhin et al. (1999) SDS-PAGE result. In Zolotukhin et al. study, AAV was purified 
from crude lysate and Lanes 5, 6 and 7 are AAV fractions recovered in the Iodixanol density 
gradient. Lane 5 fraction was collected between 40%-60% interface and fractions 6 and 7 were 
collected from the 40% density. Lane (+) contains purified AAV virus as a positive control. The lane 
marked M contains protein standards (Zolotukhin et al., 1999). 
 
Other methods can be used for AAV purification. In particular, before the adaptation of iodixanol 
gradient, the most used method was caesium chloride (CsCl), and this method is still used in many 
studies (Iwata et al., 2013). However, the challenge in using this reagent is the large amount of 
time spent in performing multiple rounds of CsCl gradient to decontaminate AAV stocks from 
aggregates, this leads to poor AAV recovery and affects AAV infectivity when the stocks are not 
properly purified (Zolotukhin et al., 1999; Auricchio et al., 2001). Furthermore, the AAV vectors 
stock must be cesium chloride-free due to the reagent toxicity to cells which must be removed 
before their transduction.  
When comparing the two methods, the non-toxicity of Iodixanol to cells makes AAV purification 
quicker when AAV infectivity assays are needed to be performed directly on AAV-Iodixanol 
gradient fractions without further purification (Iwata et al., 2013; Li et al., 2006). In addition, in 
terms of AAV vector infectivity, Iodixanol gradient was shown to generate the most infective AAV 
vectors over CsCl (Zolotukhin et al., 1999).The common drawback of both gradients is the limited 
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loading capacity for AAV samples which can impede large scale production of AAV vectors. 
However, this was not an issue for us as we wanted to perform a small scale production of AAV 
vectors to investigate our AAV2/5-F4/80 vector tropism and transgenes function.  
Another aspect to consider is that the concentration cycles and filtering of the Iodixanol gradient 
purified AAV stocks might further decrease the yield. Specifically it is possible that some viruses 
were attached to the concentrators and filters membrane and were not eluted. Therefore, in order 
to obtain a good yield of recombinant AAV vectors, every step needs to be carefully optimized to 
increase production yield of AAV vector to be able to perform downstream experiments.  
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CHAPTER 5  
AAV-MEDIATED MARCH-I EXPRESSION AND FUNCTIONAL TESTING 
 
5.1 Introduction 
The major histocompatibility complex class II molecules (MHC-II) are known to be responsible for 
initiating antigen-specific immune responses through presentation of antigenic peptides to CD4+ T 
lymphocytes. The immune cells that are known to efficiently express MHC-II include B cells, 
dendritic cells, and macrophage populations such as microglia in the brain. Together, these cells 
are considered professional antigen-presenting cells (APCs). Previous studies have reported that in 
immature or resting dendritic cells (DC), some MHC-II molecules are displayed on the cell surface 
but most of them are sequestered in the cytoplasm (Shin et al., 2006). Sequestration of MHC-II 
molecules coincides with the ubiquitination of the cytoplasmic tail of MHC-IIβ chain at the 
conserved lysine, and this ubiquitination induces MHC-II degradation (Cho and Roche, 2013). 
However, when cells are stimulated by pro-inflammatory stimuli, MHC-II expression is increased 
on the cell surface and their ubiquitination is lost (Shin et al., 2006). Once the activation is 
terminated, MHC-II molecules are re-localized in the cytoplasm and degraded (Shin et al., 2006, 
Cho and Roche, 2013). The MHC-II ubiquitination process in Interferon gamma (IFN-γ)-stimulated 
human primary monocytes was recently shown to be directly regulated, by a family member of 
membrane-associated RING (CH) proteins containing E3 ubiquitin ligase (MARCH-I) when cells 
were under IL-10 stimulation (Thibodeau et al, 2008). Additionally, Kawasume et al found that this 
process is necessary for the maintenance of conventional DCs functions in the resting state 
(Hoshino et al, 2009).  
Therefore, to further investigate the potential role of MARCH-I in regulating antigen presentation, 
we aimed to create an AAV vector that would induce the constitutive expression of MARCH-I in 
macrophages and microglia. Thus the expression of MHC-II would be reduced and MHC-II antigen 
presentation would be inhibited. Using our AAV-F4/80-eGFP viral plasmid, we aimed 1) to 
construct AAV-F4/80-eGFP-MARCH-I vector and 2) to confirm the expression of MARCH-I in RAW 
264.7 cells transfected with the AAV-F4/80-eGFP-MARCH-I vector by assessing the expression of 
MHC-II on the cell surface. 
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5.2  Results 
5.2.1 Construction of AAV vector containing the MARCH-I cDNA 
To drive the expression of MARCH-I  in our study; we inserted MARCH-I cDNA sequence into the 
vector AAV-F4/80-eGFP. The MARCH-I sequence and AAV-F4/80-eGFP vector were ligated at a 
molar ratio of 3:1 respectively using 0.1 units of T4 DNA ligase. The presence of MARCH-I in the 
vector recipient was confirmed via agarose gel electrophoresis of the colony PCR products (Figure 
5.1A). The gel showed an 857 bp band corresponding to MARCH-I fragment in wells 2-4, 6-8 and 
10-12 containing PCR products amplified from the AAV-F4/80-MARCH-I clone. The newly 
constructed AAV-F4/80-MARCH-I-eGFP clone (Figure 5.1C) that is 8884 bp, was purified and its 
identity verified by agarose gel electrophoresis after restriction digestion using SpeI/ ClaI (Figure 
5.1C). Digestion with these enzymes generated an 8027 bp and an 857 bp fragment corresponding 
to the vector recipient AAV-F4/80-eGFP and MARCH-I, respectively (Figure 5.1B, well 3).  
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Figure 5.1 AAV-F4/80-MARCH-I-eGFP vector construction and confirmation. A) Agarose gel (0.9%) 
electrophoresis of colony PCR products. In well C, a PCR reaction without ligation product was 
used as a negative control. The colony PCR was performed using the same protocol as described in 
chapter 3, figure 3.1A. MARCH-I sequence was amplified using the following customized primers: 
Forward 5’CCCCACTAGTATGCCCCTCCACCAGATTTC3’, reverse 
5’CCCCATCGATGACTGGTATAACCTCAGGTG3’ B) Agarose gel of digested AAV-F4/80-MARCH-I-eGFP 
clone with SpeI/ClaI restriction enzymes. A non-digested clone was used as a control in well 1. C) 
AAV-F4/80-MARCH-I-GFP vector genome organization. The newly constructed AAV-F4/80-MARCH-
I-eGFP vector plasmid is 8884 bp containing MARCH-I cDNA that is expressed under control of the 
macrophage-specific F4/80 promoter. eGFP reporter gene is used to monitor transfection 
efficiency in cells, and the internal ribosome entry site (IRES) coordinates the expression of 
MARCH-I and eGFP genes. The transgenes are flanked by two inverted   terminal repeats (ITRs) 
serotype 2. 
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5.2.2 MHC class II expression on RAW 264.7 cells 
To assess whether the AAV-F4/80-MARCH-I-eGFP vector would induce the expression of MARCH-I 
in transfected cells, we designed a functional assay that would monitor the expression of MHC-II 
on transfected cells. Because resting macrophages express only low levels of MHC-II, we first 
needed to induce MHC-II upregulation. Interferon-gamma (IFN-γ) is a pro-inflammatory cytokine 
that is very effective at up-regulating MHC-II surface expression and is necessary for host’s defence 
to pathogens (Samuel, 2001; Boehm et al., 1997).  
To ascertain the appropriate concentration of the monoclonal antibody for staining surface-
expressed MHC-II on RAW 264.7 cells, cells were treated with 20 U/mL IFN-γ and stained 24 h later 
with the rat anti-mouse MHC-II (IA/IE) conjugated to phycoerythrin (PE), using serial dilutions 
including: 1/100, 1/200, 1/400, 1/800, 1/1600, 1/2000. MHC-II expression was detected better at 
1/100 and 1/200 PE-IA/IE dilutions (Figure 5.2B). 
To identify the optimal IFN-γ concentration to induce a significant up-regulation in MHC-II surface 
expression on RAW 264.7cells, we stimulated the cells with 0-100 U/mL IFN-γ and 24 h later, 
assessed MHC-II expression by flow cytometry. Flow cytometric analysis indicated that the highest 
expression level of MHC-II was at 100 U/μl (Figure 5.2). However, this level was not significantly 
different from the other IFN-γ concentrations and even the lowest concentration used, 20 U/mL, 
was enough to significantly up-regulate MHC-II expression. Therefore, we decided to use 20 U/mL 
of IFN-γ to induce MHC-II surface expression in RAW 264.7 cells to investigate the functionality of 
the AAV-encoded MARCHI in transfected RAW 264.7 cells.  
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Figure 5.2 MHC-II expression was detected at 1/100 and 1/200 dilutions of PE-IA/IE antibody. 
Prior to staining, RAW 264.7 cells were cultured in complete DMEM in a 24-well plate. At 70% 
confluency, cells were treated with 20 U/mL IFN-γ and incubated at 37°C, 5% CO₂. RAW 264.7 cells 
were harvested 24 h later and stained with different dilutions of phycoerythrin (PE)-conjugated rat 
anti-mouse MHC-II (IA/IE) or with an isotype control antibody, PE-conjugated rat IgG2b (Appendix). 
A) 5000-10,000 live events were collected per assay, and the geometric mean fluorescent intensity 
(GeoMean) of MHC-II was assessed. B) comparison between different PE-IA/IE antibody dilutions. 
Detection of MHC-II surface expression was greater at 1/100 and 1/200 dilutions. 
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Figure 5.3.  All concentrations of INF- γ induced significant up-regulation of MHC-II surface 
expression on RAW 264.7.  A) RAW 264.7 cells treated with IFN-γ and left unstained (Mock) . B) 
Cells were stimulated with serial concentrations of IFN-γ (0-100 U/mL) for 24 h and stained with 
optimized concentration of PE-IA/IE (1/200) or with an isotype control antibody, PE-conjugated rat 
IgG2b.  5000-10,000 live events were collected per assay, and the geometric mean fluorescent 
intensity (GeoMean) of MHC-II was assessed. C) Shown are the means and SD of triplicates wells 
from one representative experiment of three replicates. The significance of MHC-II expression was 
compared under each concentration of INF-γ using unpaired t test with Weltech’s correction of 
one-way ANOVA test.   
 
5.2.3  Functional AAV-Mediated MARCH-I expression testing in RAW 264.7  
To verify the function of MARCH-I in regulating antigen presentation process and to test the 
usefulness of our AAV-F4/80-MARCH-I-eGFP vector, we began our experiment by forcing the 
expression of MARCH-I in RAW 264.7 cells by transfecting these cells with AAV-F4/80-MARCH-I-
eGFP. We elected to use AAV-CAG-eGFP as a control in this experiment instead of AAV-F4/80-eGFP 
vector, as the AAV-F4/80-eGFP plasmid quality decreased resulting in low eGFP expression and 
purifying another plasmid was time consuming; Therefore we decided to use AAV-CAG-eGFP 
plasmid as an alternative control. Twenty four hours post-transfection, cells were treated with 20 
U/mL IFN-γ to prime MHC-II surface expression or left untreated.  EGFP and MHC-II expression was 
assessed simultaneously at day 0 pre-IFN-γ treatment (for eGFP only), day 1, day 2 and day 3 via 
fluorescence microscopy and flow cytometry. 
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5.2.3.1 Good expression of eGFP in RAW 264.7 cells before IFN-γ treatment  
Prior to stimulating cells with IFN-γ, we visualized eGFP expression 24 h post-transfection using 
fluorescence microscopy to assess transfection efficacy. Figure 5.4 shows the expression of eGFP 
from RAW 264.7 cells transfected with either AAV-F4/80-MARCH-I-eGFP or AAV-CAG-eGFP vectors 
and suggests that eGFP fluorescence was brighter and slightly increased under the F4/80 promoter 
control compared to the CAG promoter (Figure 5.4B). The level of expression was consistent in all 
wells containing AAV-F4/80-MARCH-I-eGFP-transfected RAW 264.7 cells and indicated an efficient 
transfection of RAW 264.7 cells. Additionally, the expression of eGFP is comparable to if not better 
than our previous experiments (Chapter 2, Figure 3.5). The improved transfection efficacy may be 
due to the use of early passaged cells (i.e. sixth vs fifteenth passage). 
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Figure 5.4. Good expression of eGFP under both promoters F4/80 and CAG in RAW 264.7 prior to 
IFN-γ stimulation. RAW 264.7 cells were maintained in complete DMEM until they became 70% 
confluent. Cells were transfected in duplicate with the AAV-F4/80-MARCH-I or AAV-CAG plasmid, 
and plates were incubated at 37°C in 5% CO2. After 24 h, eGFP fluorescence was assessed by 
fluorescence microscopy, scale bar: 100 µm. 
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5.2.3.2 EGFP fluorescence in RAW 264.7 was lost after IFN-γ treatment 
Although eGFP was well expressed 24 h post transfection, after stimulating cells with 20 U/mL of 
IFN-γ for 24 h, we observed a sharp decrease in eGFP expression in cells transfected with the AAV 
vectors compared to non-IFN-γ treated transfected cells, in which reporter gene expression 
remained stable through the time course (Figure 5.5B and Figure 5.6 C, D). Using flow cytometry, 
we quantified the eGFP expression over time and found a significant decrease in eGFP expression 
when transfected cells were stimulated with IFN-γ, and this decrease was equivalent for both 
vectors (Figure 5.5). In addition, we observed that cells density in the transfected cells appeared to 
be much lower than in non-transfected cells (Figures 5.4A and 5.4B). This assay has been repeated 
several times with the same result verifying the consistency of our findings. Finally, we also 
attempted to induce MHC-II expression via IFN-γ stimulation prior to the transfection of the RAW 
264.7 cells with AAV vectors, but eGFP fluorescent cells were hardly detected the day after their 
transfection (data not shown).  
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Figure 5.5 EGFP expression was stronger under F4/80 promoter than under CAG promoter. Prior 
to transfection, RAW 264.7 cells were maintained in complete DMEM in 24-well plates. At 70% confluency, 
complete DMEM media was changed and replaced by a reduced serum complete media (2% FCS). Cells 
were transfected in duplicate with the AAV-F4/80-MARCH-I or AAV-CAG plasmid, and plates were 
incubated at 37°C in 5% CO2. After 96 h, eGFP fluorescence was assessed by fluorescence microscopy. A) 
Comparison between AAV-CAG—eGFP- transfected and non-transfected cells under light microscope. B) At 
96 h post transfection, eGFP is expressed using either vector when no IFN-γ is present. Shown are 
representative images of non-transfected or transfected (AAV-F4/80-MARCH-I or AAV-CAG-eGFP) cells 
taken using the fluorescence microscope. Scale bar: 200 μm, magnification 10x. 
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Figure 5.6.  A sharp decrease of eGFP fluorescence occurred 24 hr after IFN-γ stimulation. RAW 
264.7 cells were treated with IFN-γ at 20 U/mL 24 h post-transfection, and the cells were 
incubated at 37°C, 5% CO2 for 1-3 days. Panel A and B show RAW 264.7 cell confluency in non-
transfected (A) and transfected cells with AAV-CAG-eGFP vector control (B), respectively. EGFP 
expression from AAV-F4/80-MARCH-I or AAV-CAG –eGFP transfected cells was visualized at each 
time point using fluorescence microscopy (C, D respectively). Scale bar: 200 μm, magnification 10x. 
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Figure 5.7. EGFP expressions in transfected cells decreased after RAW 264.7 IFN-γ stimulation 
compared to non-IFN-γ stimulated cells. A) Less eGFP+ cells are detected at day 3 post IFN-γ treatment, 
when transfected cells are cultured in the presence of IFN-γ. RAW 264.7 AAV-transfected cells that were 
not treated with IFN-γ were harvested at day three. eGFP expression was quantified in each sample by flow 
cytometry and shown are representative flow plots. B) EGFP expression was reduced in IFN-γ-treated cells 
at all time points compared to non-IFN-γ-treated AAV-transfected cells. Shown are the means and SD of 
duplicate wells from one representative experiment of 3 independent replicates. EGFP expression in IFN-γ-
treated and non-treated AAV-transfected cells was compared against a mock using one way ANOVA with 
Sidak’s post hoc  multiple comparison test. **P < 0.01. 
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5.2.3.3 IFN-γ-induced MHC-II expression was impaired in AAV-transfected RAW 
264.7  
We examined MHC-II expression after transfection with the AAV-F4/80-MARCH-I-eGFP vector as a 
method to assess if a functional MARCH-I was expressed by transfected cells. Although eGFP 
expression was dramatically decreased after treatment with IFN-γ, eGFP+ cells were still present at 
day one post transfection.  MHC-II surface expression was analysed on IFN-γ-stimulated, non-
transfected or transfected cells by flow cytometry in presence and absence of MARCH-I (i.e. IFN-γ 
with AAV-F4/80-MARCH-I-eGFP or the AAV-CAG-eGFP vector control). We observed a significant 
expression of MHC-II in non-transfected RAW 264.7 cells which peaked at day 2, indicating that 20 
U/mL of IFN-γ treatment efficiently primed the induction of MHC-II in these cells (Figure 5.8B). In 
contrast, MHC-II expression was very low not only in AAV-F4/80-MARCH-I-eGFP transfected cells 
but also in cells transfected with AAV-CAG-eGFP control, which was not expected (Figure 5.8A, B). 
However, MHC-II expression was 2-fold lower in AAV-F4/80-MARCH-I-eGFP-transfected cells at day 
3 compared with that in AAV-CAG-eGFP-transfected cells (Figure 5.8B), suggesting that MHC-II 
expression may be further reduced by the presence of MARCH-I.  
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Figure 5.8. MHC-II expression was impaired on the surface of AAV-transfected RAW 264.7 cells 
after IFN-γ treatment. A) RAW 264.7 cells were analysed by flow cytometry for MHC-II surface 
expression at day 1, day 2 and day 3. Surface expression of MHC-II was measured by flow 
cytometry with PE-labeled rat anti-mouse MHC-II (IA/IE) antibodies. 5000-10,000 live events were 
collected per assay. Shown are representative flow plots from one of three experiments. B) 
Comparison of MHC-II expression between AAV-transfected and non-AAV transfected cells over 
time. Shown are the means and SD of duplicate wells from one representative experiment of three 
replicates and are expressed as the geometric mean (GeoMean) of the fluorescent intensity. Test 
for significance was performed using one way ANOVA with Sidak’s post hoc multiple comparison 
test. *P < 0.05, **P < 0.01. 
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5.2.3.4 Identification of eGFP positive cell population that did not express MHC-II 
after AAV-F4/80-MARCH-I-eGFP transfection  
Although the previous results suggested that a functional MARCH-I may be expressed in the AAV-
F4/80-MARCH-I-eGFP transfected cells; the expression of both eGFP and MHC-II that was reduced 
on all AAV-transfected cells following IFN-γ treatment weakened this conclusion considerably.  
Thus we attempted to verify at a cellular level whether the few cells that were expressing eGFP 
expressed MHC-II, in order to confirm that if MARCH-I proteins were expressed in a cell, MHC-II 
expression would be reduced. At day 1, we observed that the cells that were highly expressing 
eGFP were not expressing MHC-II in MARCH-I-containing cells, and this eGFP⁺ population was still 
present at day 2 but not day 3 (Figure 5.7), consistent with eGFP fluorescence attenuation (Figure 
5.4 C). In contrast, the CAG-containing cells expressed both eGFP and MHC-II (eGFP⁺/MHC-II⁺), and 
we did not observe the same eGFP⁺/MCH-II- population as seen in the MARCH-I-containing cells. 
This finding suggests that in MARCH-I-containing cells, MHC-II surface expression was impaired and 
provides evidence that the AAV-F4/80-MARCH-I-eGFP vector induces the expression of a 
functional MARCH-I protein.   
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Figure 5.9.   EGFP⁺/MHC-II⁻ population was identified in MARCH-I-containing cells but not in 
CAG-containing cells.  A) Transfected and non-transfected RAW 264.7 cells were treated with IFN-
γ at 20 U/mL or left untreated. B) Cells were harvested at day 1, day 2 and day 3. Prior to FACS 
analysis, cells were stained with PE-conjugated rat anti-mouse MHC-II (IA/IE), washed, and 
collected in FACS buffer. Upper panel shows eGFP⁺ cells and lower panel represents the surface 
level of MHC-II in the live single cells. The GFP⁺/MHC-II⁻ population is indicated in each circle in the 
upper left corner of each plot.  
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5.3 Discussion 
Previous studies have demonstrated that the expression of the major histocompatibility 
complexes MHC-I or MHC- II is regulated by ubiquitination through the human ubiquitin ligase 
MARCH proteins (Bartee et al, 2004, Grimm et al., 2003). These proteins were shown to be 
structurally and functionally related to the viral K3 family that helps virus evasion from host 
immune response, by inducing a rapid internalization of their target substrates from the cell 
surface (Bartee et al, 2004). In Bartee et al. for instance, transient expression of MARCH-IV and 
MARCH-IX was found to down regulate MHC-I surface expression in transfected HeLa cells. 
Similarly, ubiquitination of surface expressed-MHC-II was found to be induced by MARCH-I in 
mouse B cells (Matsuki et al., 2007), in dendritic cells (Cho and Roche, 2013) and in human primary 
monocytes (Thibodeau et al, 2008). In the latter study, five members of the MARCH family were 
tested to identify the mediator of IL-10 that is directly involved in inhibiting the MHC-II antigen-
presentation process. Although MARCH-I and MARCH-VIII were found to be the most potent 
family members to down-regulate MHC-II surface expression, a high level of MARCH I mRNA 
expression was found when cells were induced by IL-10 leading to endocytosis of MHC-II via 
ubiquitination (Thibodeau et al, 2008).  
In the hope of finding similar result, we conducted comparable experiment as previously described 
(Thibodeau et al, 2008), except that MARCH-I expression was mediated via the AAV-F4/80-
MARCH-I-eGFP viral vector. RAW 264.7 cells were treated with IFN-γ, a potent inducer of MHC-II 
expression on macrophages and other cell types (Steimle et al., 1994; Pestka and Langer, 1987). 
Stimulation of macrophages with IFN-γ activates CIITA, a trans-activator gene that induces MHC-II 
expression (Steimle et al, 1994). Upon activation, MHC-II molecules bind to peptides generated 
from exogenous proteins degradation by proteases in an endosome, and the MHC-II-peptide 
complexes are transported to the cell surface and induce T CD4⁺ cells activation (Cho and Roche, 
2013).  
 However, in contrast to our expectations, we observed a loss of eGFP fluorescence in IFN-γ 
treated cells in all AAV-transfected cells including the AAV-CAG-eGFP control vector and the AAV-
F4/80-MARCH-I-eGFP vector. This loss of eGFP was combined with a reduction in MHC-II surface 
expression in the same cells. A possible explanation is that IFN-γ treatment of AAV-transfected 
macrophages induced an antiviral response stimulating MHC-I expression and according to 
Takaoka et al., IFN-γ treatment of mouse cells might prime the induction of the anti-viral cytokine 
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INF-β in response to a viral infection (Takaoka et al.2000). In this mechanism, viral proteins are 
fragmented in the cytosol and the fragments are loaded on MHC-I molecules and transported to 
the cell surface to induce T CD8⁺ cells-mediated immune response (Komatsu et al., 1996; Farra and 
Schreider, 1993; Costa et al, 2002). This may explain the loss of eGFP fluorescence and low MHC-II 
surface expression following IFN-γ treatment of AAV-transfected macrophages (Figure 5.4). 
Furthermore, the apparent inhibition of AAV-infected cell growth that occurred following the 
treatment may serve to prepare the cells for apoptosis to prevent virus spread (Pestka and Langer, 
1987). Thus, the antiviral state that IFN-γs stimulate in infected cells may be interfering with the 
assay (58). This anti-viral hypothesis is based on many studies that demonstrated the anti-viral 
activity of IFN-γ (Komatsu et al., 1996; Liu et al, 2001), however, in order to verify it, MHC-I 
expression needs to be assessed by FACS analysis.  
While we were unable to demonstrate a direct effect of MARCH-I on MHC-II surface display using 
this approach, a more in depth analysis of eGFP positive cells allowed us to detect a difference in 
MHC-II expression between cell transfected with AAV-CAG-eGFP and AAV-F4/80-MARCH-I-eGFP. 
The eGFP+ cells that were present after AAV-F4/80-MARCH-I-eGFP transfection were not 
expressing MHC-II, whereas, the eGFP+ cells in the AAV-CAG-eGFP transfected population were still 
expressing MHC-II (Figure 5.7).  In addition, MHC-II surface expression was 2-fold lower in MARCH-
I- containing cells than that in vector control-containing cells. Thus, despite the loss of a high 
amount of eGFP in transfected cells, we were able to confirm the role of MARCH-I in inducing 
MHC-II sequestration in the cytoplasm in the remaining eGFP positive cell population in 
transfected cells.  
However, this result needs further investigation in order to confirm it, including MARCH-I mRNA 
quantification via qPCR before and after cells treatment with IFN-γ. Furthermore, in order to 
appreciate the effect of MARCH-I on MHC-II sequestration before losing eGFP, analysing the cells 
at 16 hours post-IFN-γ treatment might give us a consistent result, or considering other stimuli 
that would prime MHC-II surface expression in AAV-transfected cells while maintaining the viral 
plasmids. Lipopolysaccharide (LPS) might be a good candidate to consider as a replacement of IFN-
γ to prime MHC-II expression. It was shown in Gassart et al study that upon stimulation of APCs 
with LPS, MHC-II surface expression is increased in the surface, leading to an increase of antigen 
presentation while MARCH-I mRNA expression is decreased (Gassard et al, 2008). Therefore, if we 
prime MHC-II expression in RAW 264.7 cells with LPS and 24 h later we force MARCH-I expression 
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by transfecting cells with AAV-F4/80-MARCH-I-eGFP or with a vector control, we may have a more 
sensitive way to assess the effect of MARCH-I on MHC-II surface expression and sequestration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Page 107 
 
CHAPTER 6  
GENERAL DISCUSSION 
 
AAV has been extensively used as a viral vector in gene therapy in pre-clinical studies and clinical 
trials, due to its lack of toxicity and non-pathogenicity to humans and the long-term expression of 
the transgene. It has been extensively used to investigate and treat CNS disorders such as 
neurodegenerative diseases, in particular Alzheimer and Parkinson’s diseases (Mueller and Flotte, 
2008). Although microglia have been shown to play a critical role in neurodegeneration by 
initiating and perpetuating a chronic inflammation (Rogove et al., 2002; Frederik Vilhardt. 2004), 
most of the AAV vectors employed to study or attempt to cure these conditions target neurons 
(Iwata et al., 2013; Bishop et al., 2008; Lim et , 2009). Moreover, the potential of AAV vectors to 
dissect neuroinflammatory disorders such as multiple sclerosis has not been fully utilized yet. 
Therefore, the ultimate goal of this thesis was to create an AAV-based viral tool that would target 
microglia specifically and deliver a gene of interest, in order to investigate the role of these CNS 
resident immune cells in neuronal degeneration in MS, and other neurodegenerative disorders. 
We began our investigation by constructing an AAV-based viral tool that is driven by the human 
macrophage marker element F4/80 (EMR1). We then demonstrated the specificity of the vector 
for macrophages by comparing its activity in human cell lines with macrophage cell line RAW cells. 
Producing packaged AAV-F4/80 vector was very challenging and the low titer of AAV-F4/80 virions 
obtained prevented us from pursuing this line of investigation. Despite the antiviral action of IFN-γ 
that induced AAV-F4/80-MARCH-I vector attenuation in RAW cells, we were able to see the effect 
of MARCHI on class II MHC surface expression at the cellular level via flow cytometry.  
 
6.1 AAV-mediated gene delivery  
The use of selective targeting in gene therapy to control therapeutic gene expression is 
advantageous, and can only be achieved by the utilisation of a tissue-specific promoter. Among the 
several advantages of using a specific promoter in an AAV vector is the stable and prolonged 
transgene expression. For instance, it was documented previously that the neuron-specific enolase 
(NSE) promoter generated a strong, stable and widespread GFP expression in neurons lasting more 
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than 19 months in the rat substancia nigra with no apparent attenuation (Peel and Klein, 2000). 
While in During et al., primate neurons were transfected in vivo via an AAV expression cassette 
containing human tyrosine hydroxylase and aromatic amino acid decarboxylase driven by the CMV 
promoter, the expression of the vector did not last longer than 2.5 months (Peel and Klein, 2000). 
Although CMV hybrid promoters, which are a combination of CMV early enhancer element and a 
mammalian element, such as CMV/human β-globin promoter or CMV/chicken β-actin (CAG) 
promoter, have shown to achieve a long-term and robust  transgene expression (Peel and Klein, 
2000; Mandel et al., 1998), these promoters are still not specific and the off-target expression 
effect is very high (Chen et al., 1999.).  
Additionally, Toscano et al. indicated that non-controlled transgene expression generates 
cytotoxicity induced by an unwanted transgene expression in non-target cells and with the use of 
tissue-specific promoter this side effect is reduced completely (Toscano et al., 2011). 
 Therefore, to prevent the previously described side effects and control the expression of the viral 
tool, we elected to use an element specific to microglia in the CNS (i.e. F4/80) to drive the 
expression of the AAV vector exclusively in these cells in vivo. Although F4/80 is also expressed on 
other cells of the myeloid lineage outside of the CNS, RFP-labelled AAV vector driven by the 
murine F4/80 marker element was shown in a study conducted by Cucchiarini et al. to be the most 
discriminating for microglia compared with CD11b and CD68, when rat primary microglia and 
neuronal cultures were transduced in vitro and in vivo (Cucchiarini et al, 2003).  In addition, the 
physiological level of F4/80 expression was reported to be dependent on the biological status of 
the cells (Siamon Gordon, 2010); its expression is relatively low in blood monocytes and highly 
expressed in resident macrophages (McKnight and Gordon, 1998; Francke et al. 2011). 
Nevertheless, despite its heterogeneous expression, F4/80 is present constitutively on the cell 
surface which is beneficial in viral vector-based gene therapy as its expression is constant, 
compared with CD11b for instance that was shown to be highly up-regulated in activated 
monocytes while in resting monocytes, CD11b is down-regulated (Minghetti et al. 2005).  
Since F4/80 promoter activity in other types of cells has never been investigated, we transfected 
different human cell lines in vitro, including HEK 293, HepG2 and 1A9 cells and macrophage-like 
RAW cells via our newly constructed AAV-F4/80 vector and compared F4/80 promoter activity in 
these cells against a widely expressed promoter CAG.  Although it was evident from Cucchiarini et 
al. that F4/80 is the best currently available promoter to use for driving transgene expression to 
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microglia (Cucchiarini et al, 2003), we anticipate that our viral tool driven by F4/80 will be 
expressed in other tissue macrophages (peritoneal cavity, lung, skin epidermis, spleen, thymus and 
liver) in vivo (Gordon et al. 2011). Nonetheless, this depends on the vector delivery method, as 
stereotaxic injection of AAV virus was shown previously to be adjacent and distal to the injection 
tract (During et al., 1998; Fan et al., 2008), therefore limiting vector expression to microglia and 
infiltrating macrophages in the site of inflammation (Wolfgang Bruck, 2005). Tissue specific 
promoters have been shown to express transgenes very efficiently compared with general 
promoters (Peel and Klein, 2000; Shevtsova et al., 2004). However, in our study, eGFP expression 
under F4/80 promoter control in RAW cells was not as high as we anticipated. This might be due to 
the low transfection efficiency of these cells compared to HEK cells or, because RAW cells are 
different from primary macrophages since it is a transformed cell line. Hence, we suggest that a 
higher transgene expression may be achieved in vivo (Hartley et al, 2008). Moreover, the human 
origin of the F4/80 promoter cDNA (EMR1) may explain the low expression of eGFP in murine 
macrophage-like RAW cells due to species differences (Appendix 2B); it would be interesting to see 
if the reporter gene expression is higher in human macrophages under human EMR1 element. 
In AAV-mediated gene therapy and in particular CNS studies, AAV serotype 2 has been used 
extensively in preclinical investigations and clinical trials due to the high tropism of this serotype to 
neurons, astrocytes and microglia (Mueller and Flotte. 2008; Gonga et al., 2004). However, despite 
the success use of AAV 2 in animal studies, this serotype was shown previously to induce humoral 
and cellular immune responses in some clinical trials (Herzog, 2010; Mingozzi et al., 2007). In 
Manno et al. study for instance, AAV2-mediated delivery of human factor IX to seven patients with 
severe haemophilia, generated a CD8⁺ T cell-mediated immunity targeting AAV2 capsid antigens, 
causing destruction of transduced hepatocytes resulting in a decreased in factor IX expression 
associated with a transient asymptomatic elevation of liver transaminases (Manno et al.,2006; 
Mingozzi et al., 2007). In addition, while AAV2 mediated brain therapy resulted in successful long-
term therapeutic gene expression, due to the tolerance of the brain to foreign antigens (Wu et al., 
2009), in McPhee et al. study, AAV2 intracranial infusion that 10 Canavan disease patients have 
received, generated humoral immune response in 3 of them, where AAV2-neutralizing antibodies 
were detected in these patients’ serum (McPhee et al., 2006). Nevertheless, despite the absence 
of neutralizing antibodies in their cerebrospinal fluid (McPhee et al., 2006), a long term monitoring 
is necessary to confirm the safety of the serotype. 
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Therefore, in order to evade neutralizing antibodies to AAV2 capsids components, we decided to 
employ a hybrid construct encoding rep from AAV serotype 2 whereas cap is derived from 
serotype 5. The selection of this serotype capsid was based on the study published by Cucchiarini 
et al., where AAV serotype 5 was shown to display a high tropism for microglia (Cucchiarini et al, 
2003). In addition, instead of using the serotype 5 in our studies we elected to choose a 
pseudotype, since it was shown in previous studies that pseudotyping approach generated a 
greater gene transfer compared with serotypes (Manuel Goncalves, 2005; Daya and Berns, 2008). 
To produce our viral vector, we implemented Zolotukhin et al. method using HEK 293 as packaging 
cells (Zolotukhin et al., 1999). Despite the successful results that other researchers have achieved 
in producing AAV using this approach, we found this method very challenging as each production 
parameter required careful optimization for an optimal production of AAV. The very low titer of 
the recombinant virus that was obtained in this study was definitely not due to the large size of 
AAV genome, as it did not exceed the wild type genome size (~3.4 kb). We believe that the first 
barrier in the production process was the calcium phosphate transfection method, which was not 
efficient according to the GFP fluorescence images of calcium phosphate-mediated HEK 293 cells 
transfection (Chapter 4, figure 4.2), since less than 50% of cells were transfected. This might be 
due to the low quality of HEK cells or failure in maintaining transfection reagents at their optimal 
conditions (Fraser Wright, 2009). Iodixanol density gradient purification was another major 
obstacle that we believe affected AAV production. Our SDS PAGE result (Chapter 4, figure 4.5) 
showed contamination of purified AAV stocks with cellular proteins accompanied with very low 
titer of VP proteins, suggesting a mis-collection of the virus from the density gradient (Zolotukhin 
et al., 1999). Therefore, the low titer of the AAV-F4/80 virus precluded further investigation which 
requires a high titer of virus to validate its specificity for microglia in vivo.  
 
6.2 Microglia role in neurodegeneration investigation 
Among the acquired functions of activated microglia in the healthy brain include regulation of T 
cell responses through antigen presentation and secretion of pro-inflammatory cytokines (e.g TNF-
α, IL-1β), chemokines, and proteases, generation of reactive oxygen (ROS) species and nitrogen 
intermediates (Francesca Aloisi, 2001). Although microglia function is to protect the CNS and 
maintain its homeostasis, evidence has accumulated since decades regarding the role of these 
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resident macrophages in inducing chronic inflammation in neurodegenerative and 
neuroinflammatory disorders (Minghetti et al. 2005). It remains unclear whether this chronic 
reaction has a protective or detrimental role, since no direct evidence of the functional role of 
microglia has been found yet in these disorders. For instance, it was reported in previous studies 
that activated microglia is directly involved in stimulating inflammatory T cells infiltration in the 
CNS and this stimulation is perpetuated during the effector phase of EAE model generating 
encephalomyelitis (Becher et al, 2001; Becher et al, 2003; Cua et al., 2003).  In addition, Ulvestad 
et al. have previously demonstrated in vitro that microglia cells are potent APCs (Ulvestad et al., 
1994), whereas in vivo studies  of Ford et al. and Greter et al. showed that infiltrating macrophages 
population, but not microglia, is the effective APC in presenting antigens to CD4⁺ T cells in the MS 
model (Ford et al.,1995; Greter et al., 2005). To address this ambiguity, we aimed in this thesis to 
examine the antigen-presenting abilities of microglia, by forcing the expression of the anti-
inflammatory protein MARCHI in RAW cells using our constructed viral tool that, to our knowledge, 
has not been used for any macrophages/microglia functional studies.   
To make a detailed observation of the regulatory role of MARCHI on MHC-II, we used IFN-γ as an 
inducer of MHC-II surface expression in vitro. This pro-inflammatory cytokine was suggested to be 
the only efficient inducer of class-II (HLA-DR) MHC molecules compared with INF-α/β, and it has 
been used extensively in assays involving antigen-presentation function (Ulvestad et al., 1994; 
Samuel, 2001; Tang et al, 2012). However the usage of this pro-inflammatory cytokine in our assay 
was very challenging, as IFN-γ stimulation before or after transfecting RAW cells with AAV vectors 
induced eGFP attenuation, possibly due to the anti-viral activity of IFN-γ since this pro-
inflammatory cytokine is known to induce immune response to infected cells (Pestka and Langer. 
1987; Stark et al. 1998; Zhang et al., 2009), leading to degradation of both AAV-F4/80-MARCHI and 
AAV-CAG viral plasmids. This phenomenon did not occur in Thibodeau et al. study, as the loss of 
eYFP fluorescence was not observed following IFN-γ addition, when primary monocytes were 
transfected with a non-viral vector (Thibodeau et al, 2008). Another strong evidence supported 
our hypothesis was, the absence of MHC-II surface expression in the IFN-γ-treated cells 
transfected with the vector control. Similar result was obtained in AAV-F4/80-MARCHI transfected 
cells, compared with the treated non-transfected cells, in which MHC-II was highly expressed, 
suggesting an induced MHC-I surface expression instead of MHC-II. Although it was documented 
previously that both MHC-I and MHC-II play an important role in immune response to infections 
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and that their levels are increased during viral infection (Samuel, 2001; Boehm et al. 1997), we did 
observe a slow increase of MHC-II surface expression during the time course in AAV-CAG 
transfected cells (Chapter 5, figure 5.6) and no MHC-II increase was observed in AAV-F4/80-
MARCHI transfected cells, suggesting a down-regulatory effect of MARCHI.  However, MHC-I 
immunostaining of IFN-γ treated RAW cells as well as MARCHI mRNA quantification need to be 
performed in order to confirm the antiviral activity of IFN-γ and the effect of MARCHI in blocking 
MHC-II surface expression.  
Despite the loss of a large amount of our viral tool in RAW cells following their IFN-γ treatment, we 
were able to verify the direct effect of MARCHI on MHC-II surface expression at the cellular level, 
by analysing the remaining portion of AAV transfected cells before the complete loss of eGFP 
fluorescence. Our results support previous finding (Thibodeau et al, 2008) whereby the down-
regulatory effect of MARCHI on MHC-II surface expression. Nevertheless, an alternative stimulus 
to IFN-γ such as lipopolysaccharide (LPS) that would induce MHC-II expression and maintain 
MARCHI expression in the majority of the AAV-transfected cells must be considered in order to 
appreciate MARCHI function (Gassard et al, 2008). 
 
6.3 Future prospects 
Once AAV2/5-F4/80 virus production has been optimized, future studies may involve experiments 
that will approve the selectivity of our recombinant vector for macrophages and microglia. The 
first   approach consists in mouse splenocytes transduction in vitro; this assay will generate insight 
regarding AAV2/5-F4/80 expression in macrophages vis-a vis other cell types such as lymphocytes 
(T cells and B cells), plasma cells and dendritic cells (Mark Cesta, 2006). The effectiveness of the 
vector in delivering the transgene to microglia as well as to verify the tropism of AAV2/5-F4/80 
vector packaged into the serotype-5 capsid for these cells, as reported in Cucchiarini et al., can be 
assessed by transduction of adult mouse brain in vivo via a stereotaxic injection. In addition, to 
obtain complete information regarding AAV2/5-F4/80 virus itinerary, a systemic injection 
(Intraperitoneal or intravascular injection) may be performed. This assay will verify Iwata et al. 
finding concerning the ability of AAV to penetrate the blood-brain barrier and the possibility to 
reach microglia via systemic administration (Iwata et al., 2013). The pathway of the recombinant 
virus will be monitored via eGFP fluorescence.  
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To obtain a better understanding of MARCHI role in down regulating MHC-II surface expression, in 
vitro transduction of primary activated microglia via AAV-F4/80-MARCHI may be performed. 
However, prior to draw any conclusion from in vitro experiments, in vivo transduction of the brain 
EAE animal model must be considered as it will certainly generate greater insight regarding the 
role of  chronic inflammation in inducing neuronal demyelination in MS and other degenerative 
diseases, since microglia are targeted in the environment where they are normally found.   
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APPENDICES 
 
Appendix 1: Plasmids maps and sequences 
 
 
Figure 1A. Plasmids maps. A) Plasmid donor for mouse MARCH-I cDNA obtained from OriGene. 
The size of MARCH-I cDNA is 858 bp. B) F4/80 promoter plasmid donor obtained fron 
GeneCopoeia™. The size of the promoter is 1362 bp. C) AAV-CAG-eGFP vector plasmid map. The 
plasmid is obtained from Gene transfer vector core at the university of Iowa. The plasmid size is 
8364 bp. D) Helper plasmid map obtained from Gene transfer core. The plasmd contains the three 
adenovirus genes necessary for AAV packaging (E2A, E4 and VA genes).  
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Appendix 2: Plasmids sequences 
A. AAV-F4/80-MARCH-I-eGFP clone sequence (8894 bp) 
CCATTCGCCATTCAGGCTGCAAATAAGCGTTGATATTCAGTCAATTACAAACATTAATAACGAAGAGA
TGACAGAAAAATTTTCATTCTGTGACAGAGAAAAAGTAGCCGAAGATGACGGTTTGTCACATGGAGTT
GGCAGGATGTTTGATTAAAAACATAACAGGAAGAAAAATGCCCCGCTGTGGGCGGACAAAATAGTTG
GGAACTGGGAGGGGTGGAAATGGAGTTTTTAAGGATTATTTAGGGAAGAGTGACAAAATAGATGGGA
ACTGGGTGTAGCGTCGTAAGCTAATACGAAAATTAAAAATGACAAAATAGTTTGGAACTAGATTTCAC
TTATCTGGTTCGGATCTCCTAGGCGATATCAGTGATCAGATCCAGACATGATAAGATACATTGATGAG
TTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCT
TTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGG
TTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGCTGATTAT
GATCCTCTAGTACTTCTCGACAAGCTTACATTATTGAAGCATTTATCAGGGTTATTGTCTCAGACCTGC
AGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACCTTT
GGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGT
TCCTTGTAGTTAATGATTAACCCGCCATGCTACTTATCTACGTAGCCATGCTCTAGCGTTTAGTGAACC
GTACTAGAGGTACCGTTTAAACTCGAGGTCGACATTACAGGTGCCTAACACCATACCACACTGGCTGA
TTTTTTGTATTTTTAGTAAAGACGGGGTTTCCCCATCTTGGCCAGGCTGGTCTTGAACTCCTGACCTCG
TAATCCACCCTCCTCAGTCTCCCAAAGTGCTGAGATTACAGGTGTGAGCCACGGTGCCCGGCCATGT
CTGTATTTTCTATTTCCTTGGTGTGAGGCAATGAACCTCGGGTATTACCCCAGATGGATGACACTGCTT
CAATATCTGCCAGTCACTACACTTTGTTATCAGTGGGATTACATCAACTGGAGCCCATTCTATCTGCTT
GGAGGCCAGGCCTGAAGATTCAAGGGGTTGACACCCTCTAGGAGCAAGCCTCAAGTCAACCCATGA
CTGACAGTAGGTGGGATATAAATACCTCAGCTCCCTCACCCCTCGGTTGGAATAACTGAAGAGTATGT
TCCATGCCGCTCCCCAGTCATCCCTGGGGAGGTTAAGTTCCACTTTCTCACCATGTAACTTATTTGAAG
ACACACCCAGTATTGGCTCTTTGCCTTTCCTGATTCACTTTCTCCTCCCCCAGCTGGTGCTTTCTGGGG
CCACCTTCTTGATAAACTACTTTTGCTAGAATCCTTGTCTGAGGGTCTGCCCTTGTGAGACCCTAAGAT
GTTACCAGAGAGAGTTAGGAAGCTGGGAATGGGGTGGAAGTGTTGCTGTATAATCGTCAGACAGAGT
TGAGATCTGAAGGAAAATAAGATGGTTAAAGCTCTTGACTCTGGAATCAGAGGGTCCTGGGTTCAAAT
CTCAAGTCTGAGAGATCTTGGACAAGTTATAACTCCTCTGCAAGTCTCAGTTTCCATTTTGTTGGTGAA
TAGAGGGAGGGAGGGGAATTCCTACTTTACAAGGTTAACATGATAATGAAATTACACTTTGTTGCCAA
TGTGCCTAGCACACTGCCTGGTACATGATGGTTGTGATGGCTGTCTTTATACGGGAGACTGGGAAGAG
ACCCTAAAGGCTGAGATTTGCTTCACTGGAGGCAGGAAGCGGAAGCTCCTTTATTGGGTGCAATGAA
AGAAGGTGTTGAGAGATGGGAGATAGATGTTGATGGGAAAGAAAAAGGGAGAGACCATGGGAAGGA
GAGAGAGAGAGAATGATATACATTAGGCAGATTAACTTCTCTTTATTGTGAAGAAAGGGGGAAATTAG
GATTTTCTAGGCTGTCTTTTAGTTGCAGCAAGTCAGCAAAAAGGGCTATGATGACCAGGCAGCATTGA
GCAACTCTGACTCCGCCTTCCCCTCTTCGCACACCTTCTGGTTACTGAAAACCCAGCGTTAGTAGAAA
AGTTTCTTTTCTTTGAATGACAGAACTACAGCATAGCTAGCGTCGACACGCGTCGGCCGACACTAGT
ATGCCCCTCCACCAGATTTCTGTAATCCCAGCCCGGGAGACAGCCAGCAATGGGAGAAGTTCAATGG
GCAGAAACAAAGAGAAGAACAAGGAAGTTGAGAATGAAAAGTCCCCAGGGCGATCTGCAAGTCGAT
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CAAGTAACATATCAAAAGCAAGCAGCCCAACGACAGGGACAGCTCCCAGGAGCCAGTCAAGGTTGT
CTGTCTGTCCATCTACTCAGGACATCTGCAGGATCTGTCACTGCGAAGGAGATGAAGAGAGCCCACT
CATCACACCCTGTCGCTGCACAGGAACCTTGCGCTTTGTCCACCAGTCCTGCCTCCACCAATGGATCA
AGAGCTCAGACACACGATGCTGTGAGCTCTGCAAGTATGACTTCATAATGGAGACCAAGCTCAAGCC
CCTTCGGAAGTGGGAAAAGCTCCAGATGACCACGAGCGAAAGGAGGAAAATATTCTGCTCTGTCACG
TTCCACGTCATCGCCGTCACCTGTGTGGTGTGGTCCTTGTATGTGTTGATAGATCGGACAGCGGAGGA
AATCAAGCAAGGTAACGACAATGGTGTGCTGGAATGGCCATTTTGGACAAAACTGGTTGTGGTGGCT
ATTGGCTTCACGGGAGGTCTCGTCTTCATGTATGTACAGTGTAAAGTCTACGTCCAACTGTGGCGCCG
GCTGAAGGCCTACAACCGTGTGATCTTTGTGCAGAATTGCCCAGACACTGCCAACAAACTGGAGAAG
AACTTCCCGTGTAATGTGAACACGGAAATCAAGGATGCTGTGGTTGTGCCTGTGCCACAGACAGGTTC
AAATACACTGCCAACTGCAGAGGGAGCCCCACCTGAGGTTATACCAGTCATCGATCGGTTTAATTAA
GCTAGCGAATTCCCCGGGAAGCTTACTAGTATCGATACGCGTCGAGCATGCATCTAGGGCGGCCAAT
TCCGCCCCTCTCCCCCCCCCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAA
TAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCC
CGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCA
AGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAG
CGACCCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTG
TATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAG
AGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGT
ATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCT
AGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAAGCTTGCCACAACCCG
GGATCCAAGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCG
AGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCT
ACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGT
GACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTC
TTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACT
ACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCA
TCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACG
TCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGA
GGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
GCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGA
TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAG
TAAGCGGCCGCACTAGACCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCG
TGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCG
CATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATT
GGGAAGACAATAGCAGGCATGCTGGGGAACTAGAGCATGGCTACGTAGATAAGTAGCATGGCGGGT
TAATCATTAACTACAAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTC
ACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCA
GCTGCCTGCAGGCATGCAAGCTGTAGCCAACCACTAGAACTATAGCTAGAGTCCTGGGCGAACAAAC
GATGCTCGCCTTCCAGAAAACCGAGGATGCGAACCACTTCATCCGGGGTCAGCACCACCGGCAAGC
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GCCGCGACGGCCGAGGTCTTCCGATCTCCTGAAGCCAGGGCAGATCCGTGCACAGCACCTTGCCGTA
GAAGAACAGCAAGGCCGCCAATGCCTGACGATGCGTGGAGACCGAAACCTTGCGCTCGTTCGCCAG
CCAGGACAGAAATGCCTCGACTTCGCTGCTGCCCAAGGTTGCCGGGTGACGCACACCGTGGAAACG
GATGAAGGCACGAACCCAGTTGACATAAGCCTGTTCGGTTCGTAAACTGTAATGCAAGTAGCGTATG
CGCTCACGCAACTGGTCCAGAACCTTGACCGAACGCAGCGGTGGTAACGGCGCAGTGGCGGTTTTCA
TGGCTTGTTATGACTGTTTTTTTGTACAGTCTATGCCTCGGGCATCCAAGCAGCAAGCGCGTTACGCC
GTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACGCAGCAGCAACGATGTTACGCAGCAG
GGCAGTCGCCCTAAAACAAAGTTAGGTGGCTCAAGTATGGGCATCATTCGCACATGTAGGCTCGGCC
CTGACCAAGTCAAATCCATGCGGGCTGCTCTTGATCTTTTCGGTCGTGAGTTCGGAGACGTAGCCACC
TACTCCCAACATCAGCCGGACTCCGATTACCTCGGGAACTTGCTCCGTAGTAAGACATTCATCGCGCT
TGCTGCCTTCGACCAAGAAGCGGTTGTTGGCGCTCTCGCGGCTTACGTTCTGCCCAAGTTTGAGCAGC
CGCGTAGTGAGATCTATATCTATGATCTCGCAGTCTCCGGCGAGCACCGGAGGCAGGGCATTGCCAC
CGCGCTCATCAATCTCCTCAAGCATGAGGCCAACGCGCTTGGTGCTTATGTGATCTACGTGCAAGCAG
ATTACGGTGACGATCCCGCAGTGGCTCTCTATACAAAGTTGGGCATACGGGAAGAAGTGATGCACTTT
GATATCGACCCAAGTACCGCCACCTAACAATTCGTTCAAGCCGAGATCGGCTTCCCGGCCGCGGAGT
TGTTCGGTAAATTGTCACAACGCCGCGAATATAGTCTTTACCATGCCCTTGGCCACGCCCCTCTTTAAT
ACGACGGGCAATTTGCACTTCAGAAAATGAAGAGTTTGCTTTAGCCATAACAAAAGTCCAGTATGCTT
TTTCACAGCATAACTGGACTGATTTCAGTTTACAACTATTCTGTCTAGTTTAAGACTTTATTGTCATAGT
TTAGATCTATTTTGTTCAGTTTAAGACTTTATTGTCCGCCCACACCCGCTTACGCAGGGCATCCATTTAT
TACTCAACCGTAACCGATTTTGCCAGGTTACGCGGCTGGTCTATGCGGTGTGAAATACCGCACAGATG
CGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTC
GTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGG
ATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGT
TGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAG
GTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCT
CCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTC
TCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACG
AACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAG
ACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGT
GCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGC
TCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCT
GGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCC
TTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATtTTGGTCATGAG
ATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATA
TATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTA
TTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATC
TGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAAC
CAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTA
ATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCT
ACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAG
  Page 118 
 
GCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCA
GAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGC
CATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGG
CGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAG
TGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGT
TCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGA
GCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTC
ATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTG
AATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTG
TAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGC
CGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTT
GGAACAAGAGTCCACTATTAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGC
GATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAA
TCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAA
GGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCG
TAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTC 
 
N.B: The coloured sequences correspond to F4/80 promoter (red) and MARCH-I cDNA 
sequence (orange). Restriction enzymes are highlighted in dark green. 
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B. EMR1 and F4/80 promoters sequences comparison 
 
CLUSTAL O(1.2.1) multiple sequence alignment (F4/80 mouse Vs EMR1 human) 
 
 
EMR1       attacaggtgcctaacaccataccacactggctgattttttgtatttttagtaaagacgg 
F4/80       ------------------------------------------------------------ 
                                                                         
 
EMR1       ggtttccccatcttggccaggctggtcttgaactcctgacctcgtaatccaccctcctca 
F4/80      --------tttctcagcccgtttatcctttgagtagagg--------------------- 
                      ***  *** *  *   ***  * *   *                       
 
EMR1       gtctcccaaagtgctgagattacaggtgtgagccacggtgcccggccatgtctgtatttt 
F4/80      ------aaaactactga-------------------------------tt-----tgttt 
                  *** * ****                               *        *** 
 
EMR1       ctatttccttggtgtgaggcaatgaacctcgggtattaccccagatgg---atgacactg 
F4/80      gaattaattttatatctagccactaagctgaagttgtttatcagctgtaggagttctctg 
             ***   **  * *   ** *  ** **   **  *    *** **    *   * *** 
 
EMR1       cttcaatatctgccagtcactacactttgttatcagtgggattacatcaactggagccca 
F4/80      gtggattattttt-------tagggttatttatgtattctaccacatcatctgcaaatag 
             *  * *** *         **   **  ****   *   *  ****** *** *      
 
EMR1       ttctatctgcttggaggccaggcctgaagatt-caaggggttgacaccctctaggagcaa 
F4/80      tgatatctt---gacttcctcctttctaatttgtatccctttgacctccttttgttgcct 
            *  *****    *    **     *  *  **  *     *****  *** * *  **   
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EMR1       gcctcaag----tcaacccatgactgac--agtaggtgggatataaatacctcagctccc 
F4/80      aattgttctgggtagaactttgagtactatattaaatgataggggaaaag-tggacagcc 
              *        *  * *  *** *     * **  **  *    ** *  *   *  ** 
 
EMR1       tcacccctc---ggttggaataactgaagagtatgttccatgccgctcc----ccagtca 
F4/80      ttgggtgtggtgtgtgtggtatggtgtggtgtgtgtatggtgatgatgcatgtggtgtgt 
            *      *     **  *      **  * ** ***    **  * * *       **   
 
EMR1       tccctggggaggttaagttccactttctcaccatgtaacttatttgaagacacacccagt 
F4/80      atggtgtggtgtatgtggtgtggtgtgtggtggtggtgata--------atgatgatggt 
               ** ** *  *  * *    * * *     **    *         *        ** 
 
EMR1       attggctctttgccttt---cctgattcactttctcctcccccagctggtgctttctggg 
F4/80      ggtctctctgtctctgtctgtctctttctatctctgcctctctctctctgtctctctctg 
             *  **** *  ** *    **  ***  * *** *  * *   **    ** ***  * 
 
EMR1       gccaccttcttgataaactacttttgctagaatccttgtctgagggtctgcccttgtgag 
F4/80      cccccctctg--------------------------tctccctctgtctgtctgt--ctg 
            ** ***                             * **     ***** *  *    * 
 
EMR1       accctaagatgttaccagagagagttaggaagctgggaatggggtggaagtgttgctgta 
F4/80      tctctttggtgtgatgta-------------------tgt--------------ggtgtg 
             * **  * *** *                         *              * ***  
 
EMR1       taatcgtcagacagagttgagatctgaaggaaaataagatggt------taaagctcttg 
F4/80      tgtgtattctacaaggttgacatgatgacagaatttaattttcttagcagcaagctcatg 
           *     *   ***  ***** **    *   ** * *  *           ****** ** 
 
EMR1       a-ctctggaatcagagggtcctgggttcaaatctcaagtctgagagatcttggacaagtt 
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F4/80      gatcctggtgataaatgcagcatgactttactgaaaaggctttgtgatcttgaagagtgg 
                ****    * * *   *  *  *  * *   *** **  * ******* * *     
 
EMR1       a-taactcctctgcaagtctcagtt-----tccattttgttggtgaa-tagagggaggga 
F4/80      attgacttcactgtgggcagcacatgcaatctcacttgtttggtgtaatgaaagaagaga 
           * * *** * ***   *   **  *       ** **  ****** * *  * * ** ** 
 
EMR1       ggggaattcctactttacaaggttaacatgataatgaaattacactttgttgccaatgtg 
F4/80      atgagaggt------ggaagggggatggtaatgttgaaaaaaagaatgg-tacag----- 
              *  *            * **  *   * **  *****  *    * * * *        
 
EMR1       cctagcacactgcctggtacatgatggttgtgatggctgtctttatac-gggagactggg 
F4/80      ---aggaaactga--ggttggagagagatggggtagatggtaagagatggagaaagaggg 
              ** * ****   ***    **  * ** * * * **     * *  * ** *  *** 
 
EMR1       aagagaccctaaaggctgagatttgcttcactggaggcaggaagcggaagctcctttatt 
F4/80      aaggaaatggagagaaagacagagagacagagagagacacacagaga---gacacacaga 
            ***  *    * **   ** *            *** **   ** *      *    *   
 
EMR1       ggtgcaatgaaagaaggtgttgagagatgggagatagatgttgatgggaaagaaaaagg 
F4/80      gacagagaggaagggaaagggaaagagaa---aggaagaggaagagggggaggggaaggg 
           *   *  * *** * *   *   *****    **  *** *  ** *** * *  ** ** 
 
EMR1       gagagaccatgggaaggagagagagagagaatgatatacattaggcagattaacttctct 
F4/80      -gaaggggaagggga--agggagagggagaaatgtggacactagccagatt--------- 
               **   * *** *  ** ***** *****   *  *** *** ******          
 
EMR1       ttattgtgaagaaagggggaaattagga-ttttctaggctgtc---ttttagttgcagca 
F4/80      -----------taagggagaaattagggggttgccagtctgtccacctctgatggtggca 
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                       ***** *********   ** * ** *****    * *  * *  *** 
 
EMR1       agtcagcaaaaagggcta--tgatgaccaggcagcattgagcaactctgactccgccttc 
F4/80      actcagcagaaagctgctgggctcagtctggctttgttgagcaaccctgactccacc--- 
            * ****** ****              * ***    ********* ******** **    
 
EMR1       ccctcttcgcacaccttctggttactgaaaacccagcgttagtagaaaagtttcttttct 
F4/80      -------------ccttttcttccccacaaagcaagcttttaaagggaaggctttcttca 
                         **** *  *  *   *** * *** **   **  ***  * * ***  
 
EMR1       ttgaatgacagaactacagcata 
F4/80      ttgaatgactgccacagtacga- 
           ********* *    *   *    
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Appendix 3: Transfection optimization in RAW 264.7 and HEK 293 cells 
 
 
Figure 3A. Transfection optimization in HEK 293 cells. Twenty-four hours prior to transfection, 
HEK 293 cells were plated out in a 24-well plate at 0.4 x 10⁶ cells/well in complete DMEM. At 70% 
confluency, cells were transfected with serial amount of AAV-CAG-eGFP plasmid: 0.25 μg, 0.75 μg, 
1 μg, or left un-transfected. Transfected cells were incubated for 16-24 h at 37°C in 5% CO₂, and 
eGFP fluorescence in transfected cells was evaluated under fluorescence microscopy and 
quantified by flow cytometry.  Live cells were gated based on forward scatter (FSC-A) and side 
scatter (SSC-A) of untransfected RAW cells to exclude cell debris and doublets. GFP expression 
intensity in HEK 923 cells is shown as the geometric mean fluorescence. 
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Figure 3B. Transfection optimization in RAW 264.7 cells. RAW 264.7 cells were cultured overnight 
in 24-well plate in comple DMEM with 10% FCS using the same protocol described in figure 3A. 
cells were transfected at 70% confluency with serial amount of AAV-CAG-eGFP vector plasmid: 
0.25 μg, 0.75 μg, 1 μg, or left un-transfected. At 24 h post-transfection, eGFP fluorescence was 
examined in each well and a FACS analysis was carried out to compare fluorescence intencity in 
each sample which is shown as the geometric mean fluorescence.  
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Appendix 4: Recipies  
 
TAE buffer (x50) 
For 1 L of 50 x TAE: 
242 g Tris-HCl (pH 8.0) 
750 mL ddH₂O 
57.1 Ml glacial acetic acid 
100 mL (0.5 M) EDTA (pH 8.0) 
Adjust the solution to final volume of 1L. 
0.9 % Agarose gel (200 mL) 
1.8 g agarose powder 
200 mL 1 x TAE buffer 
FACS buffer (For flow cytometry) 
0.1% sodium azide 
97.9% PBS 
2% FCS  
Phosphate buffered saline (PBS) (10x) 
For 2 L of 10 X PBS: 
170 g NaCl (Merck Ltd, Palmerston North, New Zealand) 
62.32 g Na2HPO4.12H2O (Merck) 
4.04 g NaH2pPO4.2H2O (Merck) 
2 L ddH2O 
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LB liquid media  
For 1 L of LB solution: 
10 g Tryptone 
5 g yeast extra 
10 g NaCl  
1 L ddH₂O 
Agar medium  
For 1 L of agar medium: 
10 g Tryptone 
5 g yeast extra 
10 g NaCl  
15 g Agar 
1 L ddH₂O 
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